WO2012046845A1 - ペプチド誘導体及びその使用 - Google Patents
ペプチド誘導体及びその使用 Download PDFInfo
- Publication number
- WO2012046845A1 WO2012046845A1 PCT/JP2011/073234 JP2011073234W WO2012046845A1 WO 2012046845 A1 WO2012046845 A1 WO 2012046845A1 JP 2011073234 W JP2011073234 W JP 2011073234W WO 2012046845 A1 WO2012046845 A1 WO 2012046845A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- peptide derivative
- formula
- amino acid
- seq
- Prior art date
Links
- 0 *c1cc(C(NCCOCCOCCOCC(N*(C(N)=O)N)=O)=O)ccc1 Chemical compound *c1cc(C(NCCOCCOCCOCC(N*(C(N)=O)N)=O)=O)ccc1 0.000 description 2
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Definitions
- the present invention relates to peptide derivatives and uses thereof.
- type 2 diabetes in Japan exceeds an estimated 8.8 million people in 2007 statistics, and continues to increase further than in 2002.
- intervention before the onset of diabetes based on the glucose tolerance test is performed, but sufficient results have not been obtained.
- the cause of this is that islet damage has already progressed to a high degree at the borderline stage where functional abnormalities are revealed by a glucose tolerance test, and the start of intervention may be late.
- pancreatic islets has already decreased at the time of onset in both domestic and overseas, and further reduction of pancreatic ⁇ cells after onset is considered to be one of treatment resistance for type 2 diabetes. ing. Therefore, if the amount of pancreatic islets and / or the amount of pancreatic ⁇ -cells can be detected, there is a possibility that the etiology of type 2 diabetes and type 1 diabetes can be elucidated, diagnosed at an extremely early stage, and the onset can be prevented. For this reason, research and development of molecular probes for imaging that enable measurement of the amount of pancreatic islets and / or the amount of pancreatic ⁇ cells has been carried out.
- GLP-1R glycopeptide 1 receptor
- the present invention provides peptide derivatives useful for pancreatic ⁇ cell imaging.
- the present invention relates to a peptide derivative represented by the following general formula (I).
- ExP is exendin-4: HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO: 1)
- Ex4 (xy) represents the amino acid sequence from the x-position to the y-position of the amino acid sequence of SEQ ID NO: 1
- x is an integer of 1 to 9
- y is an integer of 30 to 39 Yes
- K represents lysine
- n is 0 or 1
- the ⁇ -amino group at the N-terminus of the polypeptide ExP is unmodified, modified with a non-charged modifying group, or linked with an -LZ group;
- the carboxyl group at the C-terminal of the polypeptide ExP is amidated
- the -LZ group represents
- the present invention relates to a peptide derivative represented by the following general formula (IV) (hereinafter, also simply referred to as “labeling precursor”), which is a labeling precursor of the peptide derivative of the present invention.
- labeling precursor a labeling precursor of the peptide derivative of the present invention.
- ExP-P is exendin-4: HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO: 1)
- Ex4 (xy) represents the amino acid sequence from the x-position to the y-position of the amino acid sequence of SEQ ID NO: 1
- x is an integer of 1 to 9
- y is an integer of 30 to 39 Yes
- K represents lysine
- n is 0 or 1
- peptide derivatives useful for pancreatic ⁇ -cell imaging preferably GLP-1R imaging of pancreatic ⁇ -cells, can be provided.
- FIG. 1 is a graph showing an example of changes over time in the biodistribution of the peptide derivative of Example 1.
- FIG. 2 is a graph showing an example of a time-dependent change in the biodistribution of the peptide derivative of Reference Example 1.
- FIG. 3 is an image showing an example of a result of two-dimensional imaging analysis using the peptide derivative of Example 1.
- FIG. 4 is an image showing an example of the results of SPECT imaging using the peptide derivative of Example 2.
- FIG. 5 is a graph showing an example of changes over time in the biodistribution of the peptide derivative of Example 3.
- FIG. 6 is a graph showing an example of a change over time of the biodistribution of the peptide derivative of Reference Example 2.
- FIG. 1 is a graph showing an example of changes over time in the biodistribution of the peptide derivative of Example 1.
- FIG. 2 is a graph showing an example of a time-dependent change in the biodistribution of the peptide
- FIG. 7 is an image showing an example of the result of two-dimensional imaging analysis using the peptide derivative of Example 3.
- FIG. 8 is an image showing an example of the results of SPECT imaging using the peptide derivative of Example 4.
- FIG. 9 is a graph showing an example of a change over time in the body distribution of Example 5.
- FIG. 10 is an image showing an example of the result of the two-dimensional imaging analysis of the fifth embodiment.
- FIG. 11 is an image illustrating an example of a result of SPECT imaging according to the sixth embodiment.
- FIG. 12 is a graph showing an example of a change over time in the body distribution of Example 7.
- FIG. 13 is an image showing an example of the result of the two-dimensional imaging analysis of the seventh embodiment.
- FIG. 14 is an image illustrating an example of a result of SPECT imaging according to the eighth embodiment.
- FIG. 15 is a graph showing an example of a change over time in the body distribution of Example 9.
- FIG. 16 is an image showing an example of the result of the two-dimensional imaging analysis of the ninth embodiment.
- FIG. 17 is a graph showing an example of a temporal change of the in-vivo distribution of Example 10.
- FIG. 18 is a graph showing an example of the radioactivity accumulation rate per gram of organ in Example 11.
- the diameter of the islets is, for example, about 50 to 500 ⁇ m for humans.
- a molecular probe that can specifically accumulate on the pancreatic islets and cause contrast with surrounding tissues is required. It is believed that. For this reason, research and development of various molecular probes as described above have been conducted, and from the viewpoint of clearer imaging or more accurate quantification, specific accumulation in the pancreas and organs around the pancreas Therefore, a new molecular probe capable of obtaining a desired contrast (S / N ratio) is demanded.
- the peptide derivative represented by the general formula (I) improves the specificity to pancreatic ⁇ cells, preferably the specificity of pancreatic ⁇ cells to GLP-1R and / or blood clearance.
- the S / N ratio is obtained based on the knowledge that, for example, a molecular probe useful for imaging by positron emission tomography (PET) or single photon radiation computed tomography (SPECT) can be provided.
- PET positron emission tomography
- SPECT single photon radiation computed tomography
- the present invention can easily produce the peptide derivative represented by the above general formula (I) by using the peptide derivative represented by the general formula (IV) as a labeling precursor. Is based on the knowledge that the yield during labeling is improved and the time required for labeling can be shortened.
- ExP is exendin-4: HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO: 1)
- SEQ ID NO: 1 A polypeptide represented by the amino acid sequence of the following formula (1) having the amino acid sequence of Ex4 (xy) -K n (1)
- Ex4 (xy) represents the amino acid sequence from the x-position to the y-position of the amino acid sequence of SEQ ID NO: 1
- x is an integer of 1 to 9
- y is an integer of 30 to 39 Yes
- K represents lysine
- n is 0 or 1
- the ⁇ -amino group at the N-terminus of the polypeptide ExP is unmodified or modified by a non-charged modifying group
- the -LZ group is bonded, the C-terminal carboxyl group of the polypeptide ExP is amidated, and the -LZ group is
- Ex4 (xy) -K n is an amino acid sequence of any one of the following formulas (2) to (5), HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (2) (SEQ ID NO: 2) HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK (3) (SEQ ID NO: 3) DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (4) (SEQ ID NO: 4) DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK (5) (SEQ ID NO: 5) [3] The -LZ group is bonded to the amino group of the side chain of lysine corresponding to position 12 of the amino acid sequence of SEQ ID NO: 1 or the amino group of the side chain of K in the formula (1).
- the C-terminal carboxyl group of the polypeptide ExP-P is amidated, and the -LY group is the amino acid sequence of the above formula (1).
- Ex4 (xy) -K n is an amino acid sequence of any one of the following formulas (2) to (5): HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (2) (SEQ ID NO: 2) HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK (3) (SEQ ID NO: 3) DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (4) (SEQ ID NO: 4) DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK (5) (SEQ ID NO: 5); [10] A kit for producing the peptide derivative according to [5], wherein Z is a labeling group containing a non-radioactive isotope of a radionuclide.
- the peptide according to any one of [1] to [4] A kit containing the derivative and / or the peptide derivative according to [8] or [9]; [11] A method for imaging pancreatic ⁇ cells, which comprises detecting a radionuclide signal of the peptide derivative from a subject previously administered with the peptide derivative of [5]; [12] The imaging method according to [11], comprising: reconstructing the detected signal, converting it into an image, and displaying the image; [13] A method for measuring the amount of pancreatic islet comprising detecting a signal of the peptide derivative from a subject administered with the peptide derivative according to [5], and calculating the amount of pancreatic islet from the signal of the detected peptide derivative; [14] The method for measuring the amount of islet according to [13], comprising presenting the calculated amount of islet; About.
- the present invention for example, there is an effect that it is possible to provide a molecular probe that is specifically accumulated in pancreatic ⁇ cells and is excellent in blood clearance and useful for imaging. Furthermore, according to the present invention, for example, since the amount of pancreatic ⁇ cells can be detected, it is possible to elucidate the etiology of diseases such as type 2 diabetes and type 1 diabetes, diagnose very early, and / or prevent the onset. It can have the effect.
- the labeling yield when performing radiolabeling is high and the time required for labeling can be shortened, it is possible to efficiently provide a molecular probe useful for imaging at a low production cost.
- the peptide derivative of the present invention has, for example, excellent specificity to pancreatic ⁇ cells, preferably excellent specificity of pancreatic ⁇ cells to GLP-1R. Moreover, the peptide derivative of the present invention is excellent in blood clearance. Therefore, the peptide derivative of the present invention can be used for imaging of pancreatic ⁇ cells, preferably quantification of pancreatic ⁇ cells, and / or GLP-1R of pancreatic ⁇ cells.
- ExP represents a polypeptide represented by the amino acid sequence of the following formula (1) having the amino acid sequence of exendin-4 (SEQ ID NO: 1) completely or partially.
- Ex4 (xy) -K n (1)
- Ex4 (xy) is the amino acid sequence from the x-position to the y-position of the amino acid sequence of SEQ ID NO: 1.
- Each of x and y represents the number of amino acid residues counted from the N-terminal side in the amino acid sequence of SEQ ID NO: 1
- x is an integer of 1 to 9
- y is an integer of 30 to 39.
- the combination of x and y is not particularly limited and can be appropriately selected.
- x is preferably 1 or 9, and y is preferably 39.
- Ex4 (xy) is preferably Ex4 (1-39) or Ex4 (9-39), for example. When x is 9 and y is 39, the amino acid sequence of Ex4 (xy) matches the amino acid sequence of exendin (9-39), which is an antagonist of GLP-1R.
- K represents a lysine residue capable of binding to the C-terminus of Ex4 (x-y), n is 0 or 1. That is, when n is 1 (K 1 ), this indicates that lysine is bound to the C-terminus of Ex4 (xy), and when n is 0 (K 0 ), Ex4 (xy) It shows that lysine is not bound to the C-terminal of.
- the lysine that binds to the C-terminus may be either L-form (L-lysine) or D-form (D-lysine), but suppresses peptide degradation from the C-terminal side in vivo and detects signals from degradation products. From the viewpoint of suppression, D-form is preferred.
- the -LZ group binds to the side chain of the amino acid of the polypeptide ExP (polypeptide having the amino acid sequence of the above formula (1)) or the ⁇ -amino group at the N-terminus, preferably the lysine of the polypeptide ExP.
- l represents the number of methylene groups
- m represents the number of oxyethylene groups.
- n in formula (1) is 1, l is 0, 1 or 2, preferably 0 or 1.
- m is an integer of 1 to 30, m is 3 to 30 from the viewpoint of suppressing the accumulation of the peptide derivative in the liver, kidney, lung and intestine and improving the ratio of pancreatic liver and pancreas and kidney.
- An integer of 4 or more, 6 or more, 8 or more, 10 or more, or 12 or more is more preferable.
- the upper limit of m is preferably an integer of 28 or less, 26 or less, 24 or less, 22 or less, 20 or less, 18 or less, 16 or less, 14 or less, or 12 or less.
- m is, for example, an integer of 1 to 14, preferably an integer of 2 to 12, more preferably an integer of 2 to 8 from the viewpoint of improving accumulation in the pancreas.
- n in the formula (1) is 0, l is an integer of 0 to 8, preferably an integer of 0 to 5, more preferably an integer of 0 to 3, and further preferably 0 or 1.
- m is an integer of 0 to 30, and m is 4 to 30 from the viewpoint of suppressing the accumulation of the peptide derivative in the liver, kidney, lung and intestine and improving the ratio of pancreatic liver and pancreas and kidney. Is more preferable, and an integer of 6 or more, 8 or more, or 10 or more is more preferable.
- the upper limit of m is preferably an integer of 28 or less, 26 or less, 24 or less, 22 or less, 20 or less, 18 or less, 16 or less, or 14 or less. Further, m is, for example, an integer from 0 to 14, preferably an integer from 0 to 12, more preferably an integer from 2 to 8, from the viewpoint of improving accumulation in the pancreas.
- Z represents a labeling group containing a radionuclide or its isotope.
- the “labeling group containing a radionuclide or an isotope thereof” includes a radionuclide and an isotope thereof.
- the isotopes include radioactive isotopes of radionuclides and non-radioactive isotopes.
- the labeling group containing the radionuclide or its isotope is not particularly limited as long as it is a group capable of binding to an amino group as shown in the above formula (II), and various known labeling groups can be used.
- radionuclide examples include 11 C, 13 N, 15 O, 18 F, 64 Cu, 67 Ga, 68 Ga, 75 Br, 76 Br, 77 Br, 82 Rb, 99m Tc, 111 In, 123 I, and 124. I, 125 I, 131 I, and 186 Re.
- the radionuclide is preferably a positron emitting nuclide such as 11 C, 13 N, 15 O, 18 F, 62 Cu, 64 Cu, 68 Ga, 75 Br, 76 Br, 82 Rb, and 124 I. .
- the radionuclide is preferably a ⁇ -ray emitting nuclide such as 67 Ga, 99m Tc, 77 Br, 111 In, 123 I, 125 I, more preferably 77 Br, 99m Tc, 111 In, 123 I or 125 I.
- radionuclides such as 18 F, 75 Br, 76 Br, 77 Br, 123 I, and 124 I are more preferable, and 18 F, 123 I, and 124 I are particularly preferable.
- the non-radioactive isotope of the radionuclide is a non-radioisotope of the above-described radionuclide, for example, 13 C, 14 N, 16 O, 17 F, 63 Cu, 70 Ga, 80 Br, 99m Tc, 115 In, And 127 I and the like.
- the labeling group containing the radionuclide or its isotope is selected from, for example, the following formula (III) from the viewpoint of the affinity between the peptide derivative and pancreatic ⁇ cell, preferably the affinity between the peptide derivative and pancreatic ⁇ cell GLP-1R. It is preferable that it is group represented by these.
- Ar represents an aromatic hydrocarbon group or an aromatic heterocyclic group.
- the aromatic hydrocarbon group is preferably an aromatic hydrocarbon group having 6 to 18 carbon atoms, such as a phenyl group, o-tolyl group, m-tolyl group, p-tolyl group, 2,4-xylyl group, p- Cumenyl group, mesityl group, 1-naphthyl group, 2-naphthyl group, 1-anthryl group, 2-anthryl group, 9-anthryl group, 1-phenanthryl group, 9-phenanthryl group, 1-acenaphthyl group, 2-azurenyl group 1-pyrenyl group, 2-triphenylenyl group, o-biphenylyl group, m-biphenylyl group, p-biphenylyl group, terphenyl group and the like.
- the aromatic heterocyclic group has 1 or 2 nitrogen atoms, oxygen atoms or sulfur atoms, and is preferably a 5- to 10-membered heterocyclic group.
- R 1 represents a radionuclide or a substituent containing an isotope thereof, for example, a radionuclide, a C 1 -C 3 alkyl group substituted by a radionuclide, a C 1 -C 3 alkoxy group substituted by a radionuclide, Examples thereof include radionuclide isotopes, C 1 -C 3 alkyl groups substituted by radionuclide isotopes, C 1 -C 3 alkoxy groups substituted by radionuclide isotopes, and the like.
- the “C 1 -C 3 alkyl group” means an alkyl group having 1 to 3 carbon atoms, and examples thereof include a methyl group, an ethyl group, and a propyl group.
- the “C 1 -C 3 alkyl group substituted by a radionuclide or an isotope thereof” has 1 to 3 carbon atoms, and a hydrogen atom is defined by the radionuclide or an isotope thereof. Refers to a substituted alkyl group.
- the “C 1 -C 3 alkoxy group” means an alkoxy group having 1 to 3 carbon atoms, and examples thereof include a methoxy group, an ethoxy group, and a propoxy group.
- the “C 1 -C 3 alkoxy group substituted by a radionuclide or an isotope thereof” has 1 to 3 carbon atoms, and a hydrogen atom is defined by the radionuclide or an isotope thereof. Refers to a substituted alkoxy group.
- R 1 is preferably a substituent containing a radioactive halogen nuclide, and more preferably a substituent containing 18 F, 75/76/77 Br, or 123/124/125/131 I, for example.
- R 1 is preferably a substituent containing a radiohalogenous species that emits positron, for example, a substituent containing 18 F, 75 Br, 76 Br, or 124 I.
- R 1 is preferably a substituent containing a radioactive halogen nuclide that emits ⁇ rays, for example, a substituent containing 77 Br, 123 I, or 125 I.
- R 1 may be any of ortho-position, meta-position and para-position, and when R 1 is 123/124/125/131 I or an isotope thereof, the meta-position is preferred, and R 1 is 18 F or an isotope thereof The para position is preferred.
- 75/76/77 Br means 75 Br, 76 Br, or 77 Br
- 123/124/125/131 I means 123 I, 124 I, 125 I, Or 131 I.
- R 2 represents a hydrogen atom or one or more substituents different from R 1 .
- R 2 may be a hydrogen atom or a substituent, but is preferably a hydrogen atom. That is, in the above formula (I), Ar is preferably not substituted with a substituent other than R 1 .
- R 2 is two or more substituents, they may be the same or different. Examples of the substituent include a hydroxyl group, an electron withdrawing group, an electron donating group, a C 1 -C 6 alkyl group, a C 2 -C 6 alkenyl group, a C 2 -C 6 alkynyl group, and the like.
- Examples of the electron withdrawing group include a cyano group, a nitro group, a halogen atom, a carbonyl group, a sulfonyl group, an acetyl group, and a phenyl group.
- Examples of the halogen atom include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
- C 1 -C 6 alkyl group refers to an alkyl group having 1 to 6 carbon atoms, such as a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, Examples thereof include a sec-butyl group, a tert-butyl group, a pentyl group, an isopentyl group, and a hexyl group.
- the “C 2 -C 6 alkenyl group” refers to an alkenyl group having 2 to 6 carbon atoms, such as a vinyl group, 1-propenyl group, 2-propenyl group, isopropenyl group, 1 -Butenyl group, 2-butenyl group, 3-butenyl group can be mentioned.
- the “C 2 -C 6 alkynyl group” refers to an alkynyl group having 2 to 6 carbon atoms, such as an ethynyl group, a 1-propynyl group, a 2-propynyl group, a 1-butynyl group, Examples include 2-butynyl group and 3-butynyl group.
- the substituent is preferably a hydroxyl group or an electron withdrawing group.
- R 3 preferably represents a bond, an alkylene group having 1 to 6 carbon atoms, or an oxyalkylene group having 1 to 6 carbon atoms.
- alkylene group having 1 to 6 carbon atoms include linear or branched alkylene groups such as a methylene group, an ethylene group, a propylene group, a butylene group, a pentylene group, and a hexylene group.
- oxyalkylene group having 1 to 6 carbon atoms include an oxymethylene group, an oxyethylene group, an oxypropylene group, an oxybutylene group, and an oxypentylene group.
- R 3 is a bond from the viewpoint of the affinity between the peptide derivative and pancreatic islets, preferably the affinity between the peptide derivative and pancreatic ⁇ -cells, more preferably the affinity between the peptide derivative and pancreatic ⁇ -cell GLP-1R.
- a methylene group and an ethylene group are preferable, and a bond is more preferable.
- the group represented by the formula (III) is represented by the formula (IIIa) from the viewpoint of the affinity between the peptide derivative and pancreatic ⁇ cell, preferably the affinity between the peptide derivative and pancreatic ⁇ cell GLP-1R.
- a group is preferable, and a group represented by the formula (IIIb) or (IIIc) is more preferable.
- R 1 is as described above.
- the group represented by the formula (III) is preferably a group represented by the formula (IIId) from the viewpoint of versatility.
- the labeling group containing a radionuclide or its isotope may contain a radionuclide and a chelate moiety capable of chelating the radionuclide from the viewpoint of labeling with a metal radioisotope (radiometal nuclide). .
- Examples of the compound capable of forming a chelate site include diethylenetriaminepentaacetic acid (DTPA), 6-hydrazinopyridine-3-carboxylic acid (HYNIC), tetraazacyclododecanetetraacetic acid (DOTA), dithisosemicarbazone (DTS), diaminedithiol ( DADT), mercaptoacetylglycylglycylglycine (MAG3), monoamidemonoaminedithiol (MAMA), diamidedithiol (DADS), propylene-diamine-dioxime (PnAO) and the like.
- DTPA diethylenetriaminepentaacetic acid
- HYNIC 6-hydrazinopyridine-3-carboxylic acid
- DTS dithisosemicarbazone
- DADT diaminedithiol
- MAG3 monoamidemonoaminedithiol
- MAMA monoamidemonoaminedithiol
- the carboxyl group at the C-terminal of polypeptide ExP is amidated with an amino group from the viewpoint of improving the binding property to pancreatic ⁇ cells and / or stability in vivo.
- the amino acid located at the C-terminus may be either L-form (L-amino acid) or D-form (D-amino acid), from the viewpoint of inhibiting peptide degradation from the C-terminal side in vivo. Is preferably D-form.
- a polypeptide polypeptide ExP is represented by Ex4 (x-y) -K 1 , if the -L-Z group is attached to K (lysine) of C-terminal, -L-Z group is bonded
- the lysine to be used is preferably D-lysine from the viewpoint of suppressing peptide degradation from the C-terminal side in vivo and suppressing signal detection from degradation products.
- the amino acid adjacent to the C-terminal lysine to which the -LZ group is bonded that is, the amino acid at the (y- (x-1)) position may be either L-form or D-form. D-form is more preferable from the viewpoint of inhibiting peptide degradation from the terminal side and inhibiting signal detection from degradation products.
- the serine at the (40-x) position may be either L-serine or D-serine, and D-serine is preferred from the same points as described above.
- the ⁇ -amino group at the N-terminus of the polypeptide ExP may be unmodified, or the charge may be reduced from the point of canceling the accumulation of the peptide derivative in the kidney by canceling the positive charge of the ⁇ -amino group at the N-terminus. It may be modified with a modifying group that does not have. Alternatively, the -LZ group may be bonded to the N-terminal ⁇ -amino group.
- modifying group having no charge examples include 9-fluorenylmethyloxycarbonyl group (Fmoc), tert-butoxycarbonyl group (Boc), benzyloxycarbonyl group (Cbz), 2,2,2-trichloroethoxy.
- the modifying group is acetyl group, benzyl group, benzyloxymethyl group, o-bromobenzyloxycarbonyl group, t-butyl group, t-butyldimethylsilyl group, 2-chlorobenzyl group, 2,6-dichlorobenzyl group.
- a cyclohexyl group, a cyclopentyl group, an isopropyl group, a pivaloyl group, a tetrahydropyran-2-yl group, a tosyl group, a trimethylsilyl group and a trityl group are preferable, and an acetyl group is more preferable.
- Ex4 (xy) -K n is, for example, preferably Ex4 (1-39), Ex4 (1-39) -K, Ex4 (9-39), or Ex4 (9-39) -K. Specifically, it is preferably an amino acid sequence of any one of the following formulas (2) to (5).
- HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (2) (SEQ ID NO: 2)
- HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK (3) (SEQ ID NO: 3)
- DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (4) (SEQ ID NO: 4)
- DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK (5) SEQ ID NO: 5
- the —LZ group is, for example, an ⁇ -amino group at the N-terminal of the amino acid sequence of the formula (2) or a lysine at the 12th position. It is preferably bonded to the amino group of the side chain (hereinafter also referred to as “Lys12”), and more preferably bonded to the amino group of the side chain of Lys12.
- the -LZ group is a lysine at position 40 of the amino acid sequence of the formula (3) (hereinafter also referred to as “Lys40”).
- Lys40 is D-lysine in that it suppresses peptide degradation from the C-terminal side in vivo and suppresses signal detection from degradation products.
- the serine at position 39 is preferably D-serine from the same points as described above.
- the -LZ group is, for example, the ⁇ -amino group at the N-terminal of the amino acid sequence of the formula (4) or the 4-position lysine It is preferably bonded to the amino group of the side chain (hereinafter also referred to as “Lys4”), and more preferably bonded to the amino group of the side chain of Lys4.
- the -LZ group is a lysine at position 32 of the amino acid sequence of the formula (5) (hereinafter also referred to as “Lys32”).
- Lys32 is D-lysine in that it suppresses peptide degradation from the C-terminal side in vivo and suppresses signal detection from degradation products.
- the 31-position serine is preferably D-serine from the same point as described above.
- the peptide derivative of the present invention can be used, for example, for pancreatic islet imaging, preferably for pancreatic ⁇ -cell imaging, and more preferably for a molecular probe for GLP-1R imaging of pancreatic ⁇ -cells.
- the peptide derivative of this invention can be used for the imaging for the prevention, treatment, or diagnosis of diabetes, for example.
- the peptide derivative of the present invention can be used as, for example, the above-described various imaging compositions, imaging reagents, contrast agents, diagnostic imaging agents, etc. containing the peptide derivative of the present invention as an active ingredient.
- Possible forms of these compositions, diagnostic imaging agents, etc. include, for example, solutions, powders, etc. In consideration of the half-life of radionuclides and decay of radioactivity, solutions are preferable, and injection solutions are more preferable.
- the present invention relates to a peptide derivative represented by the following general formula (IV).
- the peptide derivative of this embodiment can be used, for example, as a labeling precursor for the peptide derivative of the present invention described above.
- ExP-P represents a polypeptide represented by the amino acid sequence of the following formula (1) having the amino acid sequence of exendin-4 (SEQ ID NO: 1) completely or partially.
- Ex4 (xy) -K n is the same as that of the peptide derivative of the present invention described above, among which Ex4 (1-39), Ex4 (1-39) -K, Ex4 (9-39), or Ex4 (9-39) -K is preferable, and specifically, an amino acid sequence of any one of the above formulas (2) to (5) is preferable.
- the C-terminal carboxyl group of the polypeptide ExP-P is amidated.
- the -LY group binds to the ⁇ -amino group at the side chain or N-terminal of the amino acid of the polypeptide ExP-P represented by the amino acid sequence of the above formula (1), preferably lysine of the polypeptide ExP-P A group bonded to the side chain amino group or the N-terminal ⁇ -amino group represented by the following formula (V):
- the -L- group, l and m are the same as those of the peptide derivative of the present invention described above.
- Y represents a hydrogen atom or a radioactive label-introducing group, and the peptide derivative of the present invention can be easily produced.
- labeling can be performed in a short time, and further, the effect of excellent labeling yield can be achieved. Therefore, it is preferable to show a hydrogen atom.
- the “radiolabel introduction group” means a radionuclide or a group into which a radiolabeling group containing a radionuclide can be introduced.
- the radionuclide or a radiolabeling group containing a radionuclide can be introduced means that a radiolabeled specific functional group having a radiolabel introduction group or a radiolabel introduction group can be substituted by a radionuclide, It includes the ability to bind or chelate nuclides and the ability to bind to radiolabeling groups including radionuclides.
- the radiolabel introduction group may contain a chelate moiety capable of chelating the radiometal nuclide from the viewpoint of labeling with the radiometal nuclide.
- the chelate compound that forms the chelate site is as described above.
- the radiolabeled introduction group is represented, for example, by the following formula (VI) from the viewpoint of the affinity between the peptide derivative obtained after labeling and pancreatic ⁇ -cells, preferably the affinity between the peptide derivative and pancreatic ⁇ -cell GLP-1R. And the like.
- R 4 is mesylate (OMs) group, tosylate (OTs) group, triflate (OTf) group, [ 80 Br] bromine atom, [ 127 I] iodine atom, chlorine atom, nitro group, trimethylammonium group, tin atom, alkyl tin represents a substituent having a group or an alkyl silicon group, preferably OMs group, OTs group, OTf group, [80 Br] bromine, [127 I] iodine, tin atom, alkyl tin group or an alkyl silicon group, more Preferred are [ 80 Br] bromine atom, [ 127 I] iodine atom, and tin atom.
- the alkyltin group includes a C 1 -C 6 alkyl group substituted with a tin atom, and is preferably a tributyltin group (Sn (C 4 H 9 ) 3 ).
- Examples of the alkyl silicon group include a C 1 -C 6 alkyl group substituted by a silicon atom, and a tributyl silicon group is preferable.
- R 4 may be any of the ortho, meta and para positions. From the viewpoint of preparing a labeling precursor of a fluorine-labeled body, the para position is preferable. From the point of preparing a labeling precursor of an iodine labeling body, any of ortho, meta and para positions may be used.
- the group represented by the formula (VI) is represented by the following formula (VIa) from the viewpoint of the affinity between the peptide derivative and pancreatic ⁇ -cells, preferably the affinity between the peptide derivative and pancreatic ⁇ -cell GLP-1R. More preferably, in formula (VIa), R 4 represents a [ 80 Br] bromine atom, [ 127 I] iodine atom or tin atom. In the formula (VIa), R 4 is as described above.
- the ⁇ -amino group at the N-terminus of the polypeptide ExP-P has a protecting group or —LY group attached thereto, is modified by a modifying group having no charge, or is unmodified.
- the ⁇ -amino group at the N-terminus is preferably protected with a protecting group or modified with a modifying group having no charge.
- the modifying group having no charge is as described above.
- the -LY group is, for example, the ⁇ -amino group at the N-terminus of the polypeptide ExP-P or the amino acid in the side chain of Lys12. It is preferably bonded to a group, and more preferably bonded to the amino group of the side chain of Lys12.
- the -LY group is preferably bonded to the amino group of the side chain of Lys40, and Lys40 is From the viewpoint of obtaining a peptide derivative in which peptide degradation from the C-terminal side is suppressed and signal detection from the degradation product is suppressed, D-lysine is preferable.
- the serine at position 39 is preferably D-serine from the same point as described above.
- the -LY group is, for example, the ⁇ -amino group at the N-terminus of the polypeptide ExP-P or the amino acid in the side chain of Lys4. It is preferably bonded to a group, and more preferably bonded to the amino group of the side chain of Lys4.
- Ex4 (x-y) -K n is an amino acid sequence of the formula (5)
- -L-Y group is preferably bonded to the amino group of the side chain of Lys32, Lys32, in vivo
- D-lysine is preferable.
- the 31-position serine is preferably D-serine from the same point as described above.
- the side chain of the amino acid to which the -LY group is not bonded may or may not be protected by bonding of a protecting group.
- the functional group of the side chain of the amino acid to which the —LY group is not bonded is protected by the bonding of a protecting group, more preferably. Is protected at the amino group of the side chain of lysine to which the -LY group is not bonded.
- the side chain of the amino acid to which the —LY group is not bonded is in an unprotected free state.
- the protecting group protects the functional group of the side chain of the amino acid to which the -LY group of the labeling precursor is not bound during the labeling, and preferably the -LY group is bound.
- a known protecting group capable of performing such a function can be used.
- the protective group is not particularly limited, and examples thereof include Fmoc, Boc, Cbz, Troc, Alloc, Mmt, amino group, alkyl group having 3 to 20 carbon atoms, 9-fluoreneacetyl group, 1-fluorenecarboxylic acid group, 9-fluorenecarboxylic acid group, 9-fluorenone-1-carboxylic acid group, benzyloxycarbonyl group, Xan, Trt, Mtt, Mtr, Mts, Mbh, Tos, Pmc, MeBzl, MeOBzl, BzlO, Bzl, Bz, Npys, Examples include Dde, 2,6-DiCl-Bzl, 2-Cl
- Ex4 (xy) -K n is the amino acid sequence of the formula (2)
- the -LY group is bonded to the side chain amino group of Lys12 or the N-terminal ⁇ -amino group.
- the -LY group is bonded to the side chain amino group of Lys12 or the N-terminal ⁇ -amino group
- the protecting group is bonded to the -LY group. More preferably, it is bonded to the amino group of the side chain of lysine which is not.
- the -LY group is bonded to the amino group of the side chain of Lys12, and the protective group is the side chain of lysine (Lys27) at position 27. More preferably, it is bonded to an amino group, more preferably an -LY group is bonded to an amino group on the side chain of Lys12, and a protective group is an amino group on the side chain of Lys27 and an ⁇ -amino group at the N-terminus. Bonded to the group.
- Ex4 (x-y) -K n is an amino acid sequence of the formula (3)
- -L-Y group is bonded to an amino group of the side chain of Lys40, more selective labeling
- the -LY group is bonded to the amino group of the side chain of Lys40
- the protective group is bonded to the amino group of the side chain of Lys12 and Lys27.
- the -LY group is bonded to the amino group of the side chain of Lys40
- the protecting group is bonded to the ⁇ -amino group at the N-terminus and the amino group of the side chain of Lys12 and Lys27.
- Ex4 (x-y) -K n is an amino acid sequence of the formula (4)
- -L-Y group is attached to the ⁇ - amino group of the amino group or N-terminal of the side chain of Lys4
- the -LY group is bonded to the side chain amino group of Lys4 or the N-terminal ⁇ -amino group
- the protective group is bonded to the -LY group. More preferably, it is bonded to the amino group of the side chain of lysine which is not.
- the -LY group is bonded to the amino group of the side chain of Lys4, and the side chain of lysine (Lys19) at the 19th position is the protecting group. More preferably, it is bonded to an amino group, more preferably an -LY group is bonded to an amino group on the side chain of Lys4, and a protective group is an amino group on the side chain of Lys19 and an ⁇ -amino group at the N-terminus. Bonded to the group.
- Ex4 (x-y) -K n is an amino acid sequence of the formula (5), preferably the -L-Y group is bonded to an amino group of the side chain of Lys32, more selective labeling From the viewpoint of enabling, it is more preferable that the -LY group is bonded to the amino group of the side chain of Lys32, and the protective group is bonded to the amino group of the side chain of Lys4 and Lys19.
- the -LY group is bonded to the side chain amino group of Lys32, and the protecting group is bonded to the N-terminal ⁇ -amino group and the side chain amino groups of Lys4 and Lys19.
- Examples of the form of the labeling precursor include solutions, powders, and the like. From the viewpoint of handling, powders are preferable, and lyophilized powders (lyophilized preparations) are more preferable.
- the labeling precursor includes, for example, an amino acid in which the N-terminal ⁇ -amino group is protected by a protecting group (hereinafter, an amino acid in which the N-terminal ⁇ -amino group is protected by a protecting group is referred to as “protected amino acid”), From the viewpoint of synthesizing a labeling precursor that can be synthesized using a protected amino acid having an -LY group bonded to the chain and capable of more selective labeling, an -LY group is present on the side chain. It is preferable to synthesize using a bonded protected amino acid and a protected amino acid in which the functional group of the side chain is protected by a protecting group.
- the polypeptide represented by the amino acid sequence of formula (1) is synthesized, and the functional group of the side chain of the amino acid to which the -LY group is not bonded in the synthesized polypeptide Remove the protective group of the functional group that can be labeled, re-protect the functional group of the deprotected amino acid with a protective group different from the protective group before the deprotection, and other than the functional group of the amino acid that has been protected again It is preferable to include deprotecting the protecting group of the functional group.
- Y is a hydrogen atom
- the terminal amino group of the -LY group is preferably protected.
- the present invention relates to a method for producing a peptide derivative comprising labeling the labeling precursor of the present invention.
- the peptide derivative of the present invention can be easily produced, and preferably, labeling can be performed in a short time, and further, the effect of excellent labeling yield can be achieved.
- Y is preferably a hydrogen atom, and specifically, a peptide derivative represented by the following formula (VII) is preferred.
- the peptide derivative represented by the formula (VII) is used as a labeling precursor, for example, labeling can be performed in a short time, and furthermore, the labeling yield is excellent. Can play.
- the effect that the production of by-products during labeling can be suppressed can be preferably achieved.
- the polypeptides ExP-P, l and m are as described above.
- the labeling of the labeling precursor can be performed using, for example, a labeling compound having a group represented by the above formula (III).
- a labeling compound having a group represented by the formula (III) for example, a group represented by the formula (III) is preferably a succinimidyl ester compound bonded to succinimide via an ester bond, Preferably, it is a succinimidyl ester compound represented by the following formula (VIII).
- Ar is phenyl from the viewpoint of improving the affinity of the peptide derivative to be produced with pancreatic ⁇ cells, preferably the pancreatic ⁇ cells with GLP-1R.
- R 2 is a hydrogen atom
- R 3 is preferably a bond, more preferably Ar is a phenyl group
- R 1 is a [ 18 F] fluorine atom or [ 123/124/125 / 131 I] an iodine atom
- R 2 is a hydrogen atom
- R 3 is a bond.
- a compound represented by the following formula (VIIIa) is preferable, and a compound represented by the following formula (VIIIb) ([ 18 F] N-succinimidyl 4-fluorobenzoate) and a compound represented by the following formula (VIIIc) ([ 123/124/125 / 131I ] N-succinimidyl 3-iodobenzoate).
- a compound represented by the following formula (VIIId) is preferable from the viewpoint of versatility.
- the method for producing a peptide derivative of the present invention may include deprotecting the peptide derivative by removing a protecting group that binds to the labeled peptide derivative. Deprotection can be performed by a known method according to the type of the protecting group.
- the method for producing a peptide derivative of the present invention may further include a step of purifying the labeled peptide derivative from the viewpoint of producing a radiolabeled highly pure peptide derivative.
- Purification can be performed, for example, using a known separation operation for purifying a peptide or protein. Examples of the separation operation include ion exchange chromatography, hydrophobic chromatography, reverse phase chromatography, high performance liquid chromatography (HPLC) and the like, and these may be combined as necessary.
- the method for producing a peptide derivative of the present invention may include a step of synthesizing a labeled compound having a group represented by the formula (III) used for labeling and / or a step of synthesizing a label precursor.
- the synthesis of the labeling compound and the labeling of the labeling precursor may be performed by one automatic synthesizer, and the synthesis of the labeling precursor, the synthesis of the labeling compound and the labeling of the labeling precursor are performed by one automatic synthesis. It may be performed by a device.
- Another embodiment of the method for producing a peptide derivative of the present invention relates to a method for producing a peptide derivative, which comprises labeling a labeling precursor in which Y is a radiolabeled introduction group in formula (IV).
- the label precursor include a label precursor in which Y is a chelate moiety or a group represented by the above formula (VI).
- the label precursor in which Y is a group represented by the formula (VI) include a label precursor represented by the following formula (IX).
- formula (IX) the polypeptides ExP-P, 1, m and R 4 are as described above.
- Examples of the labeling compound used for labeling in this embodiment include [ 18 F] F 2 , [ 18 F] KF, [ 123/124/125/131 I] NaI, [ 123/124/125/131 I] NH 4 I and the like compounds containing radionuclides, compounds containing radiometal nuclides, and the like.
- the reaction used for labeling is not particularly limited, and can be performed using, for example, an electrophilic substitution reaction, a nucleophilic substitution reaction, or the like. In this embodiment, as described above, for example, the above-described deprotection step and / or purification step may be further included.
- Imaging reagents In still another aspect, the present invention relates to an imaging reagent containing a peptide derivative represented by the general formula (I).
- the imaging reagent of the present invention contains a peptide derivative represented by the general formula (I) as an active ingredient, and Z preferably contains a radionuclide in the general formula (I) from the viewpoint of imaging by PET or SPECT.
- a peptide derivative that is a labeling group is included as an active ingredient.
- the form of the imaging reagent is not particularly limited, and examples thereof include solutions and powders.
- a solution is preferable from the viewpoint of the half-life and radioactivity decay of the radionuclide, and an injection solution is more preferable.
- Z is a labeling group containing a non-radioactive isotope of a radionuclide
- a powder is preferable, more preferably It is a lyophilized powder (lyophilized preparation).
- the imaging reagent of the present invention may contain a pharmaceutical additive such as a carrier.
- a pharmaceutical additive refers to a compound that has been approved as a pharmaceutical additive in the Japanese Pharmacopoeia, the American Pharmacopoeia, and / or the European Pharmacopoeia.
- the carrier for example, an aqueous solvent and a non-aqueous solvent can be used.
- the aqueous solvent include potassium phosphate buffer, physiological saline, Ringer's solution, and distilled water.
- the non-aqueous solvent include polyethylene glycol, vegetable oil, ethanol, glycerin, dimethyl sulfoxide, and propylene glycol.
- kits in still another aspect, relate to a kit comprising a peptide derivative represented by the general formula (I) and / or a labeled precursor represented by the general formula (IV).
- kit embodiments include a kit for producing the peptide derivative of the present invention, a kit for imaging pancreatic ⁇ -cells, a kit for imaging GLP-1R of pancreatic ⁇ -cells, and measurement of islet volume And a kit for preventing or treating or diagnosing diabetes.
- the kit of the present invention preferably includes an instruction manual according to each form. The instruction manual may be included in the kit or may be provided on the web.
- the form of the peptide derivative represented by the general formula (I) is not particularly limited, and examples thereof include solutions and powders.
- Z when Z is a labeling group containing a radionuclide, an injection solution is preferable from the viewpoint of the half-life of the radionuclide and attenuation of radioactivity.
- Z when Z is a labeling group containing a non-radioactive isotope of a radionuclide, either a solution or a powder may be used, but from the viewpoint of handling and storage stability, a powder is preferable, more preferably It is a lyophilized powder (lyophilized preparation).
- the form of the labeling precursor of the general formula (IV) is not particularly limited, and examples thereof include a solution and a powder. From the viewpoint of handling, a powder is preferable, and a freeze-dried powder (freeze-dried) is more preferable. Formulation).
- the kit containing the labeling precursor may contain, for example, a labeling compound used for labeling the labeling precursor, a compound used as a starting material for the labeling compound, other reagents used for radioactive labeling, and the like.
- the labeling compound is as described above, and among them, the compound represented by the formula (VIIIa) is preferable, and the compound represented by the formula (VIIIb) and the compound represented by the formula (VIIIc) are more preferable.
- the starting material include a starting material for the labeled compound represented by the formula (VIIIb) and a starting material for the labeled compound represented by the formula (VIIIc).
- Examples of the starting material for the labeled compound represented by the formula (VIIIb) include ester derivatives of 4- (trimethylammonium triflate) -benzoic acid.
- Examples of ester derivatives of 4- (trimethylammonium triflate) benzoic acid include methyl ester, ethyl ester, t-butyl ester, and pentamethyl ester.
- Examples of other starting materials for the labeled compound represented by the formula (VIIIb) include ethyl 4- (trimethylammonium triflate) benzoate, ethyl 4- (tosyloxy) benzoate, ethyl 4- (methylsulfonyloxy) benzoate and the like.
- Examples of the starting material of the labeled compound represented by the formula (VIIIc) include 2,5-dioxopyrrolidin-1-yl 3- (tributylstannyl) benzoate, 2,5-dioxopyrrolidin-1-yl 3-bromobenzoate, 2, 5-dioxopyrrolidin-1-yl 3-chlorobenzoate, 2,5-dioxopyrrolidin-1-yl 3-iodobenzoate, and the like.
- Examples of other reagents used for radiolabeling include reagents containing radionuclides used for the synthesis of labeled compounds.
- the kit of the present invention may further include a container for containing the peptide derivative represented by the general formula (I) and / or the labeled precursor of the general formula (IV).
- the container include a syringe and a vial.
- the kit of the present invention may further include, for example, a component for preparing a molecular probe such as a buffer and an osmotic pressure regulator, a device used for administration of a peptide derivative such as a syringe, and the like.
- a component for preparing a molecular probe such as a buffer and an osmotic pressure regulator
- a device used for administration of a peptide derivative such as a syringe, and the like.
- the kit containing the labeling precursor may include, for example, an automatic synthesizer for synthesizing the labeling compound.
- the automatic synthesizer can label the labeling precursor using the synthesized labeling compound, deprotect the peptide derivative after labeling, synthesize the labeling precursor, etc. Also good.
- the present invention relates to a method for imaging pancreatic ⁇ cells, which comprises imaging pancreatic ⁇ cells using the peptide derivative represented by the general formula (I).
- imaging method of the present invention since the peptide derivative of the present invention is used, imaging of pancreatic ⁇ cells, preferably imaging of GLP-1R of pancreatic ⁇ cells can be performed.
- the subject include humans and / or mammals other than humans.
- the peptide derivative is preferably a peptide derivative in which Z is a labeling group containing a radionuclide in the general formula (I).
- the imaging method of the present invention includes, as a first aspect, detecting a radionuclide signal of a peptide derivative from a subject previously administered with the peptide derivative represented by the general formula (I).
- the detection of the signal is preferably performed, for example, after administration of the peptide derivative and after a sufficient time has elapsed for detection of the signal.
- the imaging method of the present invention may include, for example, reconstructing a detected signal to convert it into an image and displaying it, and / or quantifying the detected signal to present an accumulation amount.
- the display includes, for example, displaying on a monitor and printing.
- the presentation includes, for example, storing the calculated accumulation amount and outputting it to the outside.
- the detection of the signal can be appropriately determined according to the type of radionuclide of the peptide derivative to be used, and can be performed using, for example, PET and SPECT.
- SPECT includes, for example, measuring gamma rays emitted from a subject administered with the peptide derivative of the present invention with a gamma camera.
- Measurement with a gamma camera includes, for example, measuring radiation ( ⁇ rays) emitted from the radionuclide of the peptide derivative in a certain unit of time, and preferably measuring the direction and quantity of radiation emitted in a certain unit of time. Including doing.
- the imaging method of the present invention may further include representing the distribution of the measured peptide derivative obtained by measurement of radiation as a cross-sectional image and reconstructing the obtained cross-sectional image.
- PET includes, for example, simultaneous counting of gamma rays generated by annihilation of positron and electrons from a subject administered with a peptide derivative with a PET detector, and further releases positrons based on the measurement results. It may include rendering a three-dimensional distribution of radionuclide positions.
- X-ray CT and / or MRI measurement may be performed in accordance with measurement by SPECT or PET.
- SPECT or PET a fused image obtained by fusing an image (functional image) obtained by SPECT or PET and an image (morphological image) obtained by CT or MRI can be obtained.
- the peptide derivative represented by the general formula (I) is administered to the subject, and the radionuclide signal of the peptide derivative is detected from the administered subject.
- Signal detection, reconstruction processing, and the like can be performed in the same manner as in the first embodiment.
- Administration of the peptide derivative to the subject may be local or systemic.
- the administration route can be appropriately determined according to the condition of the subject, and examples thereof include intravenous, arterial, intradermal, intraperitoneal injection or infusion.
- the dose (dose) of the peptide derivative is not particularly limited, and an amount sufficient to obtain a desired contrast for imaging may be administered, and may be, for example, 1 ⁇ g or less.
- the peptide derivative is preferably administered together with a pharmaceutical additive such as a carrier.
- the pharmaceutical additive is as described above.
- the time from administration to measurement can be appropriately determined according to, for example, the binding time of the molecular probe to pancreatic ⁇ cells, the type of molecular probe, the degradation time of the molecular probe, and the like.
- the imaging method of the second aspect may include determining the state of pancreatic islets or pancreatic ⁇ cells based on the results of imaging using the peptide derivative of the present invention. Determining the state of pancreatic islets or pancreatic ⁇ cells includes, for example, determining the presence or absence of pancreatic islets or pancreatic ⁇ cells by analyzing an image of pancreatic ⁇ cell imaging, and determining increase or decrease in the amount of pancreatic islets.
- the present invention relates to a method for measuring the amount of pancreatic islets using a peptide derivative represented by the general formula (I).
- the method for measuring the amount of pancreatic islets according to the present invention comprises detecting a signal of a peptide derivative from a subject administered with the peptide derivative represented by the general formula (I), and calculating the amount of islet from the detected signal of the peptide derivative. It is preferable to include.
- the peptide derivative is preferably a peptide derivative in which Z is a labeling group containing a radionuclide in the general formula (I).
- the amount of islet can be calculated, for example, by analyzing the amount of the detected signal, the imaging image obtained by reconstructing the signal, and the like. Further, it is possible for a person skilled in the art to quantify the object to be imaged from the result of imaging, for example, using a calibration curve or an appropriate program.
- the imaging object is, for example, an islet, preferably a pancreatic ⁇ cell, more preferably a GLP-1R of pancreatic ⁇ cell.
- the method for measuring the amount of pancreatic islets according to the present invention is preferably a method for measuring the amount of pancreatic ⁇ cells from the viewpoint of use for examination and diagnosis.
- the method for measuring the amount of islets according to the present invention may further include presenting the calculated amount of islets.
- Presenting the calculated amount of islets includes, for example, storing or outputting the calculated amount of islets to the outside.
- Outputting to the outside includes, for example, displaying on a monitor and printing.
- the present invention relates to a method for preventing or treating or diagnosing diabetes.
- the amount of islets (especially the amount of ⁇ -cells in the pancreas) decreases prior to abnormal glucose tolerance in the onset of diabetes, but diabetes has already been treated after reaching the stage where functional abnormalities are detected and recognized. Is at a difficult stage.
- a decrease in the amount of pancreatic islets and / or pancreatic ⁇ cells can be detected at an early stage.
- the method for diagnosing diabetes of the present invention comprises imaging pancreatic ⁇ cells using the peptide derivative of the present invention, and determining the state of the islets based on the obtained islet image and / or islet amount. Furthermore, it may include performing a diagnosis of diabetes based on the determination result.
- the determination of the islet state is performed by, for example, comparing the obtained islet image with the reference islet image, comparing the obtained islet amount with the reference islet amount, and the like. Including determining an increase or decrease or change.
- the state of the islets may be determined using an information processing apparatus. When it is determined that the amount of islets is decreasing, the information is presented and it is determined that the amount of islets is increased or maintained. Sometimes it is preferable to present that information. Diagnosis of diabetes based on the determination result includes, for example, determining the risk of developing diabetes, determining that it is diabetes, determining the degree of progression of diabetes, and the like.
- the method for treating diabetes according to the present invention includes the treatment of diabetes based on the diagnosis in addition to the diagnosis of pancreatic islet based on the imaging of pancreatic islets using the peptide derivative of the present invention.
- Islet imaging and diabetes diagnosis can be performed in the same manner as in the method for diagnosing diabetes of the present invention.
- the treatment method can include evaluating a therapeutic effect including medication and diet therapy performed on the subject by focusing on a change in the amount of islet.
- the method for treating diabetes according to the present invention comprises performing islet imaging and / or measurement of islet amount by the method of the present invention, and restoring the function of the islet based on the obtained islet image and / or islet amount. It can include evaluating.
- the method for preventing diabetes according to the present invention includes imaging of islets using the peptide derivative of the present invention, and determining the risk of developing diabetes by determining the state of the islets based on the imaging result.
- the method for preventing diabetes according to the present invention can include, for example, periodically measuring the amount of islets and checking for a tendency to decrease the amount of islets.
- the present invention relates to a method for ultra-early diagnosis of diabetes as another preferred embodiment.
- the ultra-early diagnosis method for diabetes according to the present invention includes, for example, performing an islet imaging and / or measurement of an islet amount by a method of the present invention in a medical checkup, a health checkup, and an image of the obtained islet and / or an islet amount. Determining the state of the islets based on.
- the peptide derivative of the present invention has completely or partially the amino acid sequence of exendin-4 (SEQ ID NO: 1).
- exendin-4 is a GLP-1 analog and is known to bind to GLP-1R expressed on pancreatic ⁇ cells. Therefore, since the peptide derivative of the present invention can bind to GLP-1R, and preferably binds specifically to GLP-1R, for example, imaging and quantification of GLP-1R positive cells, GLP- It can be used for diagnosis and treatment of diseases involving 1R expression. Therefore, imaging and quantification of GLP-1R-positive cells, diagnosis and / or treatment of diseases involving GLP-1R expression, etc.
- Examples of diseases involving GLP-1R expression include neuroendocrine tumors (NET).
- Examples of neuroendocrine tumors include insulinoma, small cell bronchial cancer, pancreatic cancer and the like.
- IB 3-iodobenzoyl Rink Amide MBHA Resin (trade name, manufactured by Merck): 4- (2 ', 4'-Dimethoxyphenyl-Fmoc-aminomethyl) -phenoxyacetamido-norleucyl-MBA HBTu: 1- [bisdimethylaminomethylene] -1H-benzotriazolium-3-oxide-hexafluorophosphate HOBt: 1-hydroxybenzotriazole DMF: dimethylformamide Boc-mini-PEG-3 TM (trade name, Peptide International Boc-11-Amino-3,6,9-trioxaundecanoic acid / DCHA Boc: Butoxycarbonyl group DCHA: Dicyclohexylamine WSCD: Water-soluble carbodiimide TFA: Tetrahydrofuran HOSu: N-hydroxysuccinimide IB-Cl: 3-Iodobenzoyl Rink Amide MBHA Resin (trade name, manufactured
- Rink Amide MBHA Resin (0.39 mol / g, 0.25 mmol scal) was used as a starting resin carrier.
- an amino acid raw material an Fmoc-amino acid derivative used in a usual Fmoc-peptide synthesis method was used.
- amino acids having a functional group in the side chain are Asp (OBu), Ser (OBu), Gln (Trt), Glu (OBu), Trp (Boc), Arg (Pbf), and Asn, respectively.
- Fmoc-Lys (Boc-PEG3) was used at the 4th position, and Fmoc-Lys (Mmt) was used at the 19th position.
- the raw material Fmoc-amino acid derivative was set in the reaction vessel of the peptide synthesizer, dissolved in activators HBTu, HOBt and DMF, added to the reaction vessel, and reacted.
- a protected peptide resin A1 represented by the following formula (8) was obtained.
- the side chain protecting groups are omitted except for Lys (Mmt).
- the amino acid is extended according to the sequence using Fmoc-Lys (Boc-PEG3), Fmoc-Ser (OBu), Fmoc-Leu, and Fmoc-Asp (OBu), and the protection represented by the following formula (9) Peptide resin A2 was obtained.
- the side chain protecting groups are omitted except for Lys (Boc-PEG3) and Lys (Mmt).
- Fmoc-DLSK (Boc-PEG3) QMEEEAVRLFIEWLK (Mmt) NGGPSSGAPPPS-Rink Amide MBHA (9) (SEQ ID NO: 9)
- the side chain protecting group (Mmt) at position 19 in the protected peptide resin A2 was removed by treatment with TFA-TIS-DCM (1.5: 5: 93.5 v / v), and then the Lys at position 19 was removed.
- the amino group of the side chain was converted to Fmoc using FmocOSu to obtain a protected peptide resin A represented by the formula (7).
- the above Fmoc-Lys (Boc-PEG3) was prepared by the following method. Boc-mini-PEG-3 TM was dissolved in THF, and 0.5N HCl / ethyl acetate was added dropwise thereto (pH 3-5). After removing the precipitated DCHA salt, the obtained Boc-PEG3 was converted into an active ester using WSCD.HCl and HOSu. This active ester and Fmoc-Lys were stirred in DMF at room temperature (pH 7-8) to obtain Fmoc-Lys (Boc-PEG3).
- a peptide derivative (410 ⁇ g) represented by the formula (10) is dissolved in acetonitryl, Borate Buffer (pH 7.8), and [ 125 I] N-succinimidyl3-iodobenzoate ([[ 125 I] SIB) was added, and the reaction solution was adjusted to pH 8.5 to 9.0 and reacted for 30 minutes for labeling. Thereafter, DMF and piperidine were added to perform a deprotection reaction, and the target product (IB-PEG 3 ) 12-Ex (9-39) (peptide derivative represented by the formula (6)) was obtained (radiation). Chemical yield: 48.6%, radiochemical purity:> 99%). The time required for labeling was 2.5 hours.
- the time required for the labeling is the time required for labeling the labeling precursor to obtain the target labeled product, the reaction time with the labeling compound, and the deprotection reaction after the reaction with the labeling compound. Including time, LC purification time and concentration time (the same applies hereinafter).
- a peptide derivative (SEQ ID NO: 11) represented by the following formula (11) was prepared.
- [ 125 I] IB is directly bonded to the amino group of the side chain of the 4th-position lysine residue of the amino acid sequence of SEQ ID NO: 4, and the C-terminal The carboxyl group is amidated.
- Labeling was carried out in the same manner as in Production Example 1 except that a labeling precursor (1050 ⁇ g) represented by the following formula (12) was used instead of the peptide derivative represented by the formula (10), and the target compound of the formula (11 ) was obtained (radiochemical yield: 18.4%, radiochemical purity: 96.4%). The time required for labeling was 5.5 hours.
- Fmoc-DLSKQMEEEAVRLFIEWLK Fmoc NGGPSSGAPPPS-CONH 2 (12) (SEQ ID NO: 12)
- radiolabeling is performed using a peptide derivative represented by the formula (10) in which PEG3 is bonded to the amino group of the side chain of lysine as a linker as a labeling precursor.
- the yield of the radiolabeled peptide derivative is greatly improved, The time required for this was significantly reduced. Specifically, the yield was improved from 18.4% to 48.6%, and the yield could be improved more than twice. Also, the time required for labeling was 5.5 hours to 2.5 hours, which could be shortened by 3 hours, and the labeling could be performed in half of the conventional time. Therefore, according to the labeling precursor of the present invention, since labeling can be performed efficiently, a peptide derivative that is efficiently radiolabeled can be provided.
- (IB-PEG 3 ) 40-Ex (9-39) As shown below, a peptide derivative represented by formula (13) below (SEQ ID NO: 13) ( Hereinafter, “(IB-PEG 3 ) 40-Ex (9-39)”) was prepared.
- (IB-PEG 3 ) 40-Ex (9-39) is [ 125 I] IB via the PEG3 linker to the amino group of the side chain of the 40th lysine residue of the amino acid sequence of SEQ ID NO: 5. And the C-terminal carboxyl group is amidated.
- a protected peptide resin B (SEQ ID NO: 14) represented by the following formula (14) was synthesized.
- Synthesis of the protected peptide resin B is a production example except that Fmoc-Lys (Mmt) is used as the lysine at the 4th and 19th positions, and Fmoc-Lys (Boc-PEG3) is used as the lysine at the 32nd position. 1 was performed.
- the side chain protecting groups are omitted except for Lys (Boc-PEG3) and Lys (Fmoc).
- Fmoc-DLSK (Fmoc) QMEEEAVRLFIEWLK (Fmoc) NGGPSSGAPPPSK (Boc-PEG3) -Rink Amide MBHA (14) (SEQ ID NO: 14)
- the obtained protected peptide resin B was subjected to deprotection, excision from the resin, and isolation and purification of the peptide derivative in the same manner as in Production Example 1, and the peptide derivative represented by the following formula (15) (SEQ ID NO: 15) Was obtained as a trifluoroacetate salt (lyophilized powder).
- the peptide derivative represented by the formula (15) is a labeled precursor of (IB-PEG 3 ) 40-Ex (9-39).
- the labeling is carried out in the same manner as in Production Example 1 except that the labeling precursor (400 ⁇ g) represented by the following formula (17) is used instead of the peptide derivative represented by the formula (10), and the above-mentioned formula which is the target product
- the peptide derivative represented by (16) was obtained (radiochemical yield: 33.6%, radiochemical purity:> 99%).
- the time required for labeling was 6 hours.
- Example 1 Using a peptide derivative represented by the formula (6) ((IB-PEG 3 ) 12-Ex (9-39)), biodistribution experiments and two-dimensional imaging analysis were performed.
- FIG. 1 is a graph showing an example of the change with time of accumulation of (IB-PEG 3 ) 12-Ex (9-39) in each organ.
- (IB-PEG 3 ) 12-Ex (9-39) As shown in Table 1 and FIG. 1, the accumulation of (IB-PEG 3 ) 12-Ex (9-39) in the pancreas reached a level exceeding 25% dose / g in the early stage after administration, and a high level thereafter. In particular, it exceeded 35% dose / g during the period of 15 to 60 minutes after administration.
- (IB-PEG 3 ) 12-Ex (9-39) accumulated most in the pancreas, except for the lungs, in the time zone after 15 minutes after administration, compared with the accumulation amount per unit weight.
- (IB-PEG 3 ) 12-Ex (9-39) did not show significant changes in accumulation in the thyroid, suggesting that peptide derivatives did not undergo deiodination metabolism in vivo. It was. From these points, (IB-PEG 3 ) 12-Ex (9-39) is suitable for noninvasive imaging, and is particularly suitable for imaging of noninvasive pancreatic ⁇ cells.
- the peptide derivative represented by formula (6) ((IB-PEG 3 ) 12-Ex (9-39)) is compared with the peptide derivative represented by formula (11).
- the accumulation in the liver which is an adjacent organ of the pancreas, was small, and the accumulation amount in the blood was small.
- pancreas / liver ratio pancreas accumulation amount / liver accumulation amount
- pancreas / kidney ratio pancreas accumulation amount / kidney
- pancreas / blood ratio pancreas accumulation / blood accumulation
- (IB-PEG 3 ) 12-Ex (9-39) increased the pancreas / liver ratio and pancreas / kidney ratio over time, and the pancreas / liver ratio was increased early after administration. A value exceeding 2 was shown.
- (IB-PEG 3 ) 12-Ex (9-39) has a significantly higher pancreas / blood ratio over time compared to the peptide derivative represented by formula (11), The pancreatic / blood ratio of (IB-PEG 3 ) 12-Ex (9-39) showed a value of more than 3 early after administration, indicating good blood clearance.
- pancreatic ⁇ -cell imaging is possible because of the high accumulation in the pancreas, but little accumulation in the surrounding organs of the pancreas and excellent blood clearance. It was suggested that a clear image could be obtained when
- FIG. 3 is an example of the results of imaging analysis of pancreatic sections of MIP-GFP mice administered with (IB-PEG 3 ) 12-Ex (9-39), and shows an image (upper diagram) and ( An image showing the radioactive signal of IB-PEG 3 ) 12-Ex (9-39) (below) is shown.
- a fluorescent GFP signal and a radioactive signal were detected in the pancreas section of the MIP-GFP mouse by the image analyzer.
- the localization of the radioactive signal of (IB-PEG 3 ) 12-Ex (9-39) almost coincided with the GFP signal. From these results, it was confirmed that (IB-PEG 3 ) 12-Ex (9-39) was specifically accumulated in pancreatic ⁇ cells.
- 125 I, 123 I and 131 I are all ⁇ -ray emitting nuclides. Furthermore, 125 I and 123 I have the same nuclear spin number. From these, even when the radioactive iodine atom of (IB-PEG 3 ) 12-Ex (9-39) is [ 123 I] iodine atom or [ 131 I] iodine atom, (IB-PEG 3 3 ) It is presumed to show almost the same behavior as 12-Ex (9-39). Even when [ 124 I] iodine atom is used, it is presumed that the same behavior as (IB-PEG 3 ) 12-Ex (9-39) is exhibited.
- Example 2 As shown below, three-dimensional imaging by SPECT was performed using a peptide derivative (SEQ ID NO: 18) represented by the following formula (18). Note that the peptide derivative represented by the formula (18) has a [ 123 I] 3-iodobenzoyl group (via a PEG3 linker) on the side chain amino group of the fourth lysine residue of the amino acid sequence of SEQ ID NO: 4. [ 123 I] IB) is bound, and the C-terminal carboxyl group is amidated.
- [Three-dimensional imaging] SPECT imaging of mice was performed using the peptide derivative represented by the formula (18).
- a peptide derivative represented by the formula (18) (491 ⁇ Ci (18.2 MBq) / 190 ⁇ l) was administered intravenously to 6-week-old ddY mice (male, body weight about 30 g), and inhaled with influenza from 20 minutes after the administration of the peptide derivative. Anesthesia was started. Subsequently, SPECT imaging was performed 30 minutes after administration of the peptide derivative.
- the SPECT imaging was performed using a gamma camera (product name: SPECT2000H-40, manufactured by Hitachi Medical Corporation) under the following imaging conditions. The obtained image was reconstructed under the following reconstruction conditions.
- Imaging conditions ⁇ br/> Collimator LEPH Collimator collection range: 360 [deg.] Step angle: 11.25 ° Collection time: Collection time per direction: 60 seconds 1 frame x 32 frames every 60 seconds (32 minutes in total) Reconfiguration condition ⁇ br/> Pre-processing filter: Butterworth filter (order: 10, cutoff frequency: 0.10)
- FIG. 4 An example of the result is shown in FIG.
- the image shown in FIG. 4 is 30 minutes after administration of the peptide derivative, and shows a transverse view, a coronal view, and a sagittal view in order from the left.
- the position of the pancreas is indicated by a white arrow.
- the position of the pancreas could be confirmed noninvasively in the mouse by SPECT imaging using the peptide derivative represented by the formula (18).
- the position of the pancreas was confirmed non-invasively in a mouse with a smaller pancreas size and denser organs than humans. It has been suggested that, for example, a human who has not yet been able to determine the position and size of the pancreas more clearly, and furthermore, the amount of the peptide derivative that binds to GLP-1R of pancreatic ⁇ cells can be measured.
- the peptide derivative of the present invention enables non-invasive three-dimensional imaging of pancreatic islets in humans, and in particular, non-invasive three-dimensional imaging of pancreatic ⁇ cells and pancreatic ⁇ cells GLP-1R. It was suggested that three-dimensional imaging is possible.
- Example 3 Using a peptide derivative represented by formula (13) ((IB-PEG 3 ) 40-Ex (9-39)), biodistribution experiments and two-dimensional imaging analysis were performed.
- FIG. 5 is a graph showing an example of the change with time of accumulation of (IB-PEG 3 ) 40-Ex (9-39) in each organ.
- (IB-PEG 3 ) 40-Ex (9-39) As shown in Table 6 and FIG. 5, the accumulation of (IB-PEG 3 ) 40-Ex (9-39) in the pancreas reached a level exceeding 25% dose / g early after administration, and a high level thereafter. Maintained at. In addition, (IB-PEG 3 ) 40-Ex (9-39) showed no significant change in accumulation in the thyroid, suggesting that the peptide derivative did not undergo deiodination metabolism in vivo. It was. From these points, (IB-PEG 3 ) 40-Ex (9-39) is suitable for non-invasive imaging, especially for non-invasive pancreatic ⁇ -cell GLP-1R imaging. .
- pancreas / liver ratio, pancreas / kidney ratio, and pancreas / blood ratio are shown in Tables 8, 9 and 10 below based on the amount accumulated in each organ in the in vivo distribution experiments of Example 3 and Reference Example 2, respectively.
- pancreas / liver ratio of (IB-PEG 3 ) 40-Ex (9-39) exceeded 5 at an early stage after administration.
- the pancreas / liver ratio of (IB-PEG 3 ) 40-Ex (9-39) is the pancreas / liver ratio of the peptide derivative represented by formula (16). The value exceeded 5 times.
- the pancreas / kidney ratio of (IB-PEG 3 ) 40-Ex (9-39) reached nearly 1 early after administration.
- the pancreas / blood ratio of (IB-PEG 3 ) 40-Ex (9-39) is very high compared to that of the peptide derivative represented by formula (16), and after administration The value exceeded 3.5 at an early stage, indicating good blood clearance.
- (IB-PEG 3 ) 40-Ex (9-39) which has a high accumulation amount in the pancreas, a small accumulation in the peripheral organs of the pancreas, and excellent blood clearance, It was suggested that a clear image can be obtained when imaging.
- FIG. 7 is an example of the results of imaging analysis of pancreatic sections of MIP-GFP mice administered with (IB-PEG 3 ) 40-Ex (9-39), and shows an image (upper figure) and ( An image (lower figure) showing the radioactive signal of IB-PEG 3 ) 40-Ex (9-39) is shown.
- a fluorescent GFP signal and a radioactive signal were detected by the image analyzer in the pancreas section of the MIP-GFP mouse.
- the localization of the radioactive signal of (IB-PEG 3 ) 40-Ex (9-39) was almost consistent with the GFP signal.
- Example 4 As shown below, three-dimensional imaging by SPECT was performed using a peptide derivative (SEQ ID NO: 19) represented by the following formula (19).
- the peptide derivative represented by the formula (19) has a [ 123 I] 3-iodobenzoyl group (via a PEG3 linker to the side chain amino group of the lysine residue at position 32 of the amino acid sequence of SEQ ID NO: 5). [ 123 I] IB) is bound, and the C-terminal carboxyl group is amidated.
- [Three-dimensional imaging] SPECT imaging of mice was performed using the peptide derivative represented by the formula (19).
- a peptide derivative represented by the formula (18) (500 ⁇ Ci (18.5 MBq)) was administered intravenously to 6-week-old ddY mice (male, body weight about 30 g), and influrane inhalation anesthesia was started 20 minutes after the administration of the peptide derivative. Started.
- SPECT imaging was performed 30 minutes after administration of the peptide derivative.
- the SPECT imaging was performed using a gamma camera (product name: SPECT2000H-40, manufactured by Hitachi Medical Corporation) under the following imaging conditions. The obtained image was reconstructed under the following reconstruction conditions.
- Imaging conditions ⁇ br/> Collimator LEPH Collimator collection range: 360 [deg.] Step angle: 11.25 ° Collection time: Collection time per direction 60 seconds 1 frame x 32 frames every 60 seconds (total 32 minutes) Reconstruction condition ⁇ br/> Preprocessing filter: Butterworth filter (order: 10, cutoff frequency: 0.14)
- FIG. 8 An example of the result is shown in FIG.
- the image shown in FIG. 8 is 30 minutes after administration of the peptide derivative, and shows a transverse image, a coronal image, and a sagittal image in order from the left.
- the position surrounded by the white line in the coronal image in FIG. 8 indicates the position of the pancreas.
- the position of the pancreas could be confirmed noninvasively in the mouse by SPECT imaging using the peptide derivative represented by the formula (19).
- the position of the pancreas was confirmed non-invasively in a mouse with a smaller pancreas size and denser organs than humans. It has been suggested that, for example, a human who has not yet been able to determine the position and size of the pancreas more clearly, and furthermore, the amount of the peptide derivative that binds to GLP-1R of pancreatic ⁇ cells can be measured.
- the peptide derivative of the present invention enables non-invasive three-dimensional imaging of pancreatic islets in humans, and in particular, non-invasive three-dimensional imaging of pancreatic ⁇ cells and pancreatic ⁇ cells GLP-1R. It was suggested that three-dimensional imaging is possible.
- the peptide derivative (470 ⁇ g) represented by the formula (22) is dissolved in Borate Buffer (pH 7.8), and [ 18 F] N-succinimidyl 4-fluorobenzoate ([ 18 F] SFB) is added to the reaction solution.
- DMF and piperidine were added to perform a deprotection reaction to obtain the target product (FB-PEG 3 ) 12 -Ex4 (peptide derivative represented by the formula (20)) (radiochemical yield: 10). 0.0%, radiochemical purity:> 99%).
- the time required for labeling was 2 hours.
- the peptide derivative (labeled precursor) in which PEG3 was linked to the amino group of the side chain of Lys12 was radiolabeled to bind to the amino group of the side chain of lysine.
- the yield of the radiolabeled peptide derivative was improved by 7 times or more, and the time required for labeling could be shortened by about 1 hour. Therefore, according to the labeling precursor of the present invention, it is possible to efficiently produce a radiolabeled peptide derivative.
- the peptide derivative of the formula (22) in which PEG3 was bonded to the amino group of the side chain of Lys12 was radiolabeled so that PEG3 was attached to the amino group of the side chain of lysine.
- the unlabeled labeling precursor of formula (23) was used, the purity of the obtained radiolabeled peptide derivative could be improved and the time required for labeling could be shortened by 1.1 hours.
- radiolabeling was performed using a peptide derivative of the formula (28) in which PEG3 was bonded to the amino group of the side chain of lysine as a labeling precursor, whereby Compared with the case where a labeled precursor of formula (29) in which PEG3 was not bonded to the amino group of the chain, the yield of the radiolabeled peptide derivative could be improved.
- Binding assays were performed using the four types of polypeptides shown in Table 11 below (formulas (31) to (34), all of which are cold forms).
- Binding Assay procedure The Binding Assay was performed according to the following procedure. First, islets isolated from mice were collected in a 50 ml tube, centrifuged (2000 rpm, 2 minutes), and then washed once with 20 ml of cold PBS. Add 15 mL trypsin-EDTA (3 mL trypsin-EDTA (0.05% / 0.53 mM) plus 12 mL 0.53 mM EDTA (pH 7.4 (NaOH)) containing PBS) and shake at 37 ° C. Incubate for 1 minute and place immediately on ice.
- the islet cell sample was suspended in Buffer (20 mM HEPES (pH 7.4), 1 mM MgCl 2 , 1 mg / ml bacitracin, 1 mg / ml BSA) so as to be 100 ⁇ L / tube.
- Buffer (20 mM HEPES (pH 7.4), 1 mM MgCl 2 , 1 mg / ml bacitracin, 1 mg / ml BSA) so as to be 100 ⁇ L / tube.
- Example 5 Using the peptide derivative represented by formula (25) ((IB-PEG 3 ) 12-Ex4), biodistribution experiments and two-dimensional imaging analysis were performed.
- FIG. 9 is a graph showing an example of a change with time of accumulation of (IB-PEG 3 ) 12-Ex4 in each organ.
- (IB-PEG 3 ) 12-Ex4 showed a pancreatic / liver ratio exceeding 10 early after administration.
- the pancreatic / blood ratio of (IB-PEG 3 ) 12-Ex4 exceeded 5 at an early stage after administration, indicating good blood clearance.
- pancreatic ⁇ cell imaging preferably pancreatic ⁇ cell GLP It was suggested that a clear image could be obtained when -1R imaging was performed.
- unlabeled exendin (9-39) (cold probe, SEQ ID NO: 20) was pre-administered intravenously (50 ⁇ g / 100 ⁇ l) to unanesthetized MIP-GFP mice (male, body weight 20 g). Fluorescence and radioactivity were measured in the same manner as described above except that (IB-PEG 3 ) 12 -Ex4 (5.6 ⁇ Ci / 100 ⁇ l) was administered intravenously 30 minutes later. An example of the result is shown in Blocking (+) of FIG.
- FIG. 10 is an example of the results of imaging analysis of pancreatic sections of MIP-GFP mice administered with (IB-PEG 3 ) 12-Ex4, and shows an image showing a fluorescent signal (upper figure) and an image showing a radioactive signal ( Shown below). As shown in FIG. 10, since the localization of the radioactive signal almost coincided with the GFP signal, it was confirmed that (IB-PEG 3 ) 12 -Ex4 was specifically accumulated in pancreatic ⁇ cells.
- the peptide derivative represented by the formula (35) was prepared in the same procedure as in Production Example 4 except that [ 123 I] SIB was used instead of [ 125 I] SIB.
- a peptide derivative represented by the formula (35) (153 ⁇ Ci (5.66 MBq) / 250 ⁇ l) was administered intravenously to 6-week-old ddY mice (male, body weight about 30 g), and inhaled with influenza from 20 minutes after administration of the peptide derivative. Anesthesia was started. Subsequently, SPECT imaging was performed 30 minutes after administration of the peptide derivative. The SPECT imaging was performed using a gamma camera (product name: SPECT2000H-40, manufactured by Hitachi Medical Corporation) under the following imaging conditions. The obtained image was reconstructed under the following reconstruction conditions.
- Imaging conditions ⁇ br/> Collimator LEPH Collimator collection range: 360 [deg.] Step angle: 11.25 ° Collection time: Collection time per direction: 60 seconds 1 frame x 32 frames every 60 seconds (32 minutes in total) Reconfiguration condition ⁇ br/> Pre-processing filter: Butterworth filter (order: 10, cutoff frequency: 0.10)
- FIG. 11 An example of the obtained image is shown in FIG.
- the image shown in FIG. 11 is a coronal view 30 minutes after administration of the peptide derivative, and the position surrounded by a white line indicates the position of the pancreas.
- the position of the pancreas could be confirmed noninvasively in the mouse by SPECT imaging using the peptide derivative represented by the formula (35). In this way, the position of the pancreas was confirmed non-invasively in a mouse with a smaller pancreas size and denser organs than humans.
- Example 7 Using the peptide derivative represented by formula (27) ((IB-PEG 3 ) 40-Ex4), biodistribution experiments and two-dimensional imaging analysis were performed.
- FIG. 12 is a graph showing an example of a change with time of accumulation of (IB-PEG 3 ) 40-Ex4 in each organ.
- (IB-PEG 3 ) 40-Ex4 showed a value of pancreatic / liver ratio exceeding 10 early after administration.
- the pancreatic / blood ratio of (IB-PEG 3 ) 40-Ex4 showed a value exceeding 5 at an early stage after administration, indicating good blood clearance.
- the pancreas / liver ratio is high and the blood clearance is excellent (IB-PEG 3 ) 40-Ex4 enables imaging of pancreatic ⁇ cells, preferably GLP of pancreatic ⁇ cells It was suggested that a clear image could be obtained when -1R imaging was performed.
- unlabeled exendin (9-39) (cold probe, SEQ ID NO: 20) was pre-administered intravenously (50 ⁇ g / 100 ⁇ l) to unanesthetized MIP-GFP mice (male, body weight 20 g). Fluorescence and radioactivity were measured in the same manner as described above except that (IB-PEG 3 ) 40-Ex4 (5.6 ⁇ Ci / 100 ⁇ l) was administered intravenously after 30 minutes. An example of the result is shown in Blocking (+) of FIG.
- FIG. 13 is an example of the results of imaging analysis of pancreatic sections of MIP-GFP mice administered with (IB-PEG 3 ) 40-Ex4, and shows an image showing a fluorescent signal (upper figure) and an image showing a radioactive signal ( Shown below).
- Blocking (-) in Fig. 13 the localization of the radioactive signal almost coincided with the GFP signal, confirming that (IB-PEG 3 ) 40-Ex4 specifically accumulates in pancreatic ⁇ cells. did it.
- Blocking (+) of FIG. 13 by blocking the receptor, almost no radioactive signal of (IB-PEG 3 ) 40-Ex4 was detected. Therefore, (IB-PEG 3 ) 40 It was suggested that -Ex4 was specifically accumulated in GLP-1R of pancreatic ⁇ cells.
- the peptide derivative represented by the formula (36) was prepared in the same procedure as in Production Example 5 except that [ 123 I] SIB was used instead of [ 125 I] SIB.
- Imaging conditions ⁇ br/> Collimator LEPH Collimator collection range: 360 [deg.] Step angle: 11.25 ° Collection time: Collection time per direction: 60 seconds 1 frame x 32 frames every 60 seconds (32 minutes in total) Reconfiguration condition ⁇ br/> Pre-processing filter: Butterworth filter (order: 10, cutoff frequency: 0.10)
- FIG. 14 An example of the obtained image is shown in FIG.
- the image shown in FIG. 14 is a coronal view 30 minutes after administration of the peptide derivative, and the position surrounded by a white line indicates the position of the pancreas.
- the position of the pancreas could be confirmed noninvasively in the mouse by SPECT imaging using the peptide derivative represented by the formula (36).
- Example 9 Using the peptide derivative represented by formula (24) ((FB-PEG 3 ) 12-Ex4), biodistribution experiments and two-dimensional imaging analysis were performed.
- FIG. 15 is a graph showing an example of the change with time of accumulation of (FB-PEG 3 ) 12 -Ex 4 in each organ.
- (FB-PEG 3 ) 12-Ex4 showed a pancreatic / liver ratio exceeding 10 early after administration.
- the pancreatic / blood ratio of (FB-PEG 3 ) 12-Ex4 showed a value exceeding 5 at an early stage after administration, indicating a good blood clearance.
- the pancreas / liver ratio is high and the blood clearance is excellent (FB-PEG 3 ) 12-Ex4. It was suggested that a clear image could be obtained when -1R imaging was performed.
- FIG. 16 is an example of the results of imaging analysis of pancreatic sections of MIP-GFP mice administered with (FB-PEG 3 ) 12 -Ex4, and shows an image showing a fluorescent signal (upper figure) and an image showing a radioactive signal ( Shown below). As shown in FIG. 16, since the localization of the radioactive signal almost coincided with the GFP signal, it was confirmed that (FB-PEG 3 ) 12 -Ex4 was specifically accumulated in pancreatic ⁇ cells.
- the time required for labeling was 2.75 hours.
- the time required for labeling includes reaction time with the labeled compound, HPLC purification time, deprotection reaction time after reaction with the labeled compound, LC purification time, and concentration time.
- Example 10 A biodistribution experiment was performed using a peptide derivative represented by formula (37) ((IB-ePEG 12 ) 12-Ex4).
- FIG. 17 is a graph showing an example of a change with time of accumulation of (IB-ePEG 12 ) 12 -Ex4 in each organ.
- (IB-ePEG 12 ) 12-Ex4 showed a pancreatic / liver ratio that exceeded 10 early after administration and was maintained at a high level beyond that. Moreover, the pancreatic / blood ratio of (IB-ePEG 12 ) 12-Ex4 showed a value exceeding 5 at an early stage after administration, and thereafter maintained at a high level exceeding that, indicating a good blood clearance.
- pancreatic ⁇ -cell imaging preferably GLP of pancreatic ⁇ -cells, according to (IB-ePEG 12 ) 12-Ex4, which has a high amount of accumulation in the pancreas but a high pancreatic / liver ratio and excellent blood clearance It was suggested that a clear image could be obtained when -1R imaging was performed.
- the peptide derivative represented by the formula (39) was prepared in the same procedure as in Production Example 6 except that [ 123 I] SIB was used instead of [ 125 I] SIB.
- FIG. 18 is a graph showing an example of the ratio per radiogram of organ (radioactivity accumulation rate per g of organ (% dose / g)) to the radioactivity administered in the imaged mouse. As shown in FIG. 18, accumulation in the liver, large intestine and the like was hardly observed, and good results were obtained. In addition, in the captured image, the position of the pancreas could be confirmed non-invasively (data not shown).
- the present invention is useful in, for example, the medical field, the field of molecular imaging, and the field related to diabetes.
- SEQ ID NO: 1 amino acid sequence of exendin-4
- SEQ ID NO: 2 example of amino acid sequence of peptide derivative of the present invention
- SEQ ID NO: 3 example of amino acid sequence of peptide derivative of the present invention
- SEQ ID NO: 4 amino acid sequence of peptide derivative of the present invention
- An example of SEQ ID NO: 5 An example of an amino acid sequence of the peptide derivative of the present invention
- SEQ ID NO: 6 An amino acid sequence of the peptide derivative produced in Production Example 1
- SEQ ID NO: 7 An amino acid sequence of the protected peptide resin A produced in Production Example 1
- SEQ ID NO: 9 Amino acid sequence of the protected peptide resin A2 produced in Production Example 1
- SEQ ID NO: 10 Amino acid sequence of the labeled precursor produced in Production Example 1
- 11 Amino acid sequence of the peptide derivative produced in Reference Production Example 1
- SEQ ID NO: 12 Standard used in Reference Production Example 1 Amino
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nuclear Medicine (AREA)
Abstract
Description
ExPは、exendin-4:
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (配列番号1)
のアミノ酸配列を完全に又は部分的に有する下記式(1)のアミノ酸配列で表されるポリペプチドを示し、
Ex4(x-y)-Kn (1)
式(1)において、Ex4(x-y)は、配列番号1のアミノ酸配列のx位からy位のアミノ酸配列を示し、xは1~9の整数であり、yは30~39の整数であり、Kは、リジンを示し、nは、0又は1であり、
ポリペプチドExPのN末端のα-アミノ基は、非修飾であるか、電荷を有さない修飾基により修飾されているか、又は-L-Z基が結合しており、
ポリペプチドExPのC末端のカルボキシル基は、アミド化されており、
-L-Z基は、上記式(1)のアミノ酸配列で表されるポリペプチドのアミノ酸の側鎖、又はN末端のα-アミノ基に結合する下記式(II)で表される基を示し、
式(1)におけるnが1である場合、lは0、1又は2であり、mは1~30の整数であり、式(1)におけるnが0である場合、lは0~8の整数であり、mは0~30の整数であり、
Zは、放射性核種又はその同位体を含む標識基を示す。
ExP-Pは、exendin-4:
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (配列番号1)
のアミノ酸配列を完全に又は部分的に有する下記式(1)のアミノ酸配列で表されるポリペプチドを示し、
Ex4(x-y)-Kn (1)
式(1)において、Ex4(x-y)は、配列番号1のアミノ酸配列のx位からy位のアミノ酸配列を示し、xは1~9の整数であり、yは30~39の整数であり、Kは、リジンを示し、nは、0又は1であり、
ポリペプチドExP-PのN末端のα-アミノ基は、保護基又は-L-Y基が結合しているか、電荷を有さない修飾基により修飾されているか、若しくは非修飾であり、
ポリペプチドExP-PのC末端のカルボキシル基は、アミド化されており、
-L-Y基は、上記式(1)のアミノ酸配列で表されるポリペプチドのアミノ酸の側鎖、又はN末端のα-アミノ基に結合する下記式(V)で表される基を示し、
式(1)におけるnが1である場合、lは0、1又は2であり、mは1~30の整数であり、式(1)におけるnが0である場合、lは0~8の整数であり、mは0~30の整数であり、Yは、水素原子、又は放射性標識導入基を示す。
〔1〕 下記一般式(I)で表されるペプチド誘導体;
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (配列番号1)
のアミノ酸配列を完全に又は部分的に有する下記式(1)のアミノ酸配列で表されるポリペプチドを示し、
Ex4(x-y)-Kn (1)
式(1)において、Ex4(x-y)は、配列番号1のアミノ酸配列のx位からy位のアミノ酸配列を示し、xは1~9の整数であり、yは30~39の整数であり、Kは、リジンを示し、nは、0又は1であり、ポリペプチドExPのN末端のα-アミノ基は、非修飾であるか、電荷を有さない修飾基により修飾されているか、又は-L-Z基が結合しており、ポリペプチドExPのC末端のカルボキシル基は、アミド化されており、-L-Z基は、上記式(1)のアミノ酸配列で表されるポリペプチドのアミノ酸の側鎖、又はN末端のα-アミノ基に結合する下記式(II)で表される基を示し、
式(1)におけるnが1である場合、lは0、1又は2であり、mは1~30の整数であり、式(1)におけるnが0である場合、lは0~8の整数であり、mは0~30の整数であり、Zは、放射性核種又はその同位体を含む標識基を示す;
〔2〕 Ex4(x-y)-Knは、下記式(2)~(5)のいずれかのアミノ酸配列である〔1〕記載のペプチド誘導体、
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (2) (配列番号2)
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK (3) (配列番号3)
DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (4) (配列番号4)
DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK (5) (配列番号5)
〔3〕 -L-Z基は、配列番号1のアミノ酸配列の12位に相当するリジンの側鎖のアミノ基、又は式(1)のKの側鎖のアミノ基に結合している、〔1〕又は〔2〕に記載のペプチド誘導体;
〔4〕 Zは、下記式(III)で表される基である〔1〕から〔3〕のいずれかに記載のペプチド誘導体、
〔5〕 Zは、放射性核種を含む標識基である、〔1〕から〔4〕のいずれかに記載のペプチド誘導体;
〔6〕 〔1〕から〔5〕のいずれかに記載のペプチド誘導体を含む組成物;
〔7〕 〔5〕に記載のペプチド誘導体を含むイメージング用試薬;
〔8〕下記一般式(IV)で表されるペプチド誘導体、
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (配列番号1)
のアミノ酸配列を完全に又は部分的に有する下記式(1)のアミノ酸配列で表されるポリペプチドを示し、
Ex4(x-y)-Kn (1)
式(1)において、Ex4(x-y)は、配列番号1のアミノ酸配列のx位からy位のアミノ酸配列を示し、xは1~9の整数であり、yは30~39の整数であり、Kは、リジンを示し、nは、0又は1であり、ポリペプチドExP-PのN末端のα-アミノ基は、保護基又は-L-Y基が結合しているか、電荷を有さない修飾基により修飾されているか、若しくは非修飾であり、ポリペプチドExP-PのC末端のカルボキシル基は、アミド化されており、-L-Y基は、上記式(1)のアミノ酸配列で表されるポリペプチドのアミノ酸の側鎖、又はN末端のα-アミノ基に結合する下記式(V)で表される基を示し、
式(1)におけるnが1である場合、lは0、1又は2であり、mは1~30の整数であり、式(1)におけるnが0である場合、lは0~8の整数であり、mは0~30の整数であり、Yは、水素原子、又は放射性標識導入基を示す;
〔9〕Ex4(x-y)-Knは、下記式(2)~(5)のいずれかのアミノ酸配列である、請求項8記載のペプチド誘導体、
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (2) (配列番号2)
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK (3) (配列番号3)
DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (4) (配列番号4)
DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK (5) (配列番号5);
〔10〕 〔5〕に記載のペプチド誘導体を製造するためのキットであって、Zが放射性核種の非放射性同位体を含む標識基である〔1〕から〔4〕のいずれかに記載のペプチド誘導体、及び/若しくは〔8〕又は〔9〕に記載のペプチド誘導体を含むキット;
〔11〕 膵β細胞をイメージングするための方法であって、〔5〕記載のペプチド誘導体を予め投与された被検体から前記ペプチド誘導体の放射性核種のシグナルを検出することを含むイメージング方法;
〔12〕 前記検出されたシグナルを再構成処理して画像に変換し表示することを含む〔11〕記載のイメージング方法;
〔13〕 〔5〕記載のペプチド誘導体を投与された被検体から前記ペプチド誘導体のシグナルを検出すること、及び検出したペプチド誘導体のシグナルから膵島量を算出することを含む膵島量の測定方法;
〔14〕 算出した膵島量を提示することを含む〔13〕記載の膵島量の測定方法;
に関する。
本発明のペプチド誘導体は、下記一般式(I)で表される。
Ex4(x-y)-Kn (1)
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (2) (配列番号2)
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK (3) (配列番号3)
DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (4) (配列番号4)
DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK (5) (配列番号5)
本発明は、その他の態様として、下記一般式(IV)で表されるペプチド誘導体に関する。本態様のペプチド誘導体は、例えば、上記の本発明のペプチド誘導体の標識前駆体として利用することができる。
Ex4(x-y)-Kn (1)
本発明は、さらにその他の態様として、本発明の標識前駆体を標識化することを含むペプチド誘導体の製造方法に関する。
本発明は、さらにその他の態様として、一般式(I)で表されるペプチド誘導体を含むイメージング用試薬に関する。
本発明は、さらにその他の態様として、一般式(I)で表されるペプチド誘導体及び/又は一般式(IV)の標識前駆体を含むキットに関する。キットの態様としては、例えば、本発明のペプチド誘導体を製造するためのキット、膵β細胞のイメージングを行うためのキット、膵β細胞のGLP-1Rのイメージングを行うためのキット、膵島量の測定を行うためのキット、及び糖尿病の予防又は治療又は診断のためのキット等が挙げられる。本発明のキットは、これらの各態様において、それぞれの形態に応じた取扱い説明書を含むことが好ましい。取扱い説明書は、キットに同梱されてもよいし、ウェブ上で提供されてもよい。
本発明は、さらにその他の態様として、一般式(I)で表されるペプチド誘導体を用いて膵β細胞をイメージングすることを含む膵β細胞のイメージング方法に関する。本発明のイメージング方法によれば、本発明のペプチド誘導体を用いることから、膵β細胞のイメージング、好ましくは膵β細胞のGLP-1Rのイメージングを行うことができる。被検体としては、例えば、ヒト及び/又はヒト以外の哺乳類が挙げられる。ペプチド誘導体は、一般式(I)においてZが放射性核種を含む標識基であるペプチド誘導体が好ましい。
本発明は、さらにその他の態様として、一般式(I)で表されるペプチド誘導体を用いて膵島量を測定する方法に関する。本発明の膵島量の測定方法は、一般式(I)で表されるペプチド誘導体を投与された被検体からペプチド誘導体のシグナルを検出すること、及び検出したペプチド誘導体のシグナルから膵島量を算出することを含むことが好ましい。ペプチド誘導体は、一般式(I)においてZが放射性核種を含む標識基であるペプチド誘導体が好ましい。
本発明は、さらにその他の態様として、糖尿病の予防又は治療又は診断方法に関する。上記のとおり、糖尿病の発症過程では、膵島量(とりわけ、膵β細胞量)が耐糖能異常に先行して減少するが、機能異常が検出・自覚される段階に至ってからでは、糖尿病はすでに治療が難しい段階となっている。しかし、本発明のペプチド誘導体を用いたイメージング方法及び/又は膵島量の測定方法によれば、膵島量及び/又は膵β細胞量の減少を早期に発見することができ、ひいては、新たな糖尿病の予防・治療・診断法が構築できる。糖尿病の予防・治療・診断の対象(被検体)としては、ヒト及び/又はヒト以外の哺乳類が挙げられる。
本発明のペプチド誘導体は、エキセンジン-4のアミノ酸配列(配列番号1)を完全に又は部分的に有する。上記の通り、エキセンジン-4は、GLP-1類似体であり、膵β細胞上に発現するGLP-1Rに結合することが知られている。このため、本発明のペプチド誘導体は、GLP-1Rに結合可能であり、好ましくはGLP-1Rに特異的に結合可能であることから、例えば、GLP-1R陽性の細胞のイメージング及び定量、GLP-1Rの発現が関与する疾患の診断及び治療等に利用できる。したがって、上記膵島のイメージング・定量等と同様に、GLP-1R陽性の細胞のイメージング及び定量、GLP-1Rの発現が関与する疾患の診断及び/又は治療等を行うことができる。GLP-1Rの発現が関与する疾患としては、例えば、神経内分泌腫瘍(NET)等が挙げられる。神経内分泌腫瘍としては、例えば、インスリノーマ、小細胞気管支癌、膵癌等が挙げられる。
IB:3-iodobenzoyl
Rink Amide MBHA Resin(商品名、Merck製):4-(2’,4’-Dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucyl-MBA
HBTu:1-[ビスジメチルアミノメチレン]-1H-ベンゾトリアゾリウムー3-オキシドーヘキサフルオロホスフェイト
HOBt:1-ヒドロキシベンゾトリアゾール
DMF:ジメチルホルムアミド
Boc-mini-PEG-3TM(商品名、Peptide International製):Boc-11-Amino-3,6,9-trioxaundecanoic acid・DCHA
Boc:ブトキシカルボニル基
DCHA:ジシクロヘキシルアミン
WSCD:水溶性カルボジイミド
TFA:テトラフドロフラン
HOSu:N-ヒドロキシスクシンイミド
IB-Cl:3-Iodobenzoyl chloride
DIEA:N,N-ジイソプロピルエチルアミン
OBu:ブチルエステル基
Trt:トリチル基
Pdf:2,2,4,6,7-ペンタメチルジヒドロベンゾフラン-5-スルホニル基
Mmt:4-メトキシトリチル基
Fmoc:9-フルオレニルメチルオキシカルボニル基
PEG3:-C(O)-CH2-(OC2H4)3-NH-
ePEG12:-C(O)-C2H4-(OC2H4)12-NH-
なお、アミノ酸は、特に言及しない限り、L体を使用した。
式(6)で表されるペプチド誘導体:(IB-PEG 3 )12-Ex(9-39)の合成
以下に示すように、下記式(6)で表されるペプチド誘導体(配列番号6)(以下、「(IB-PEG3)12-Ex(9-39)」ともいう)を調製した。なお、(IB-PEG3)12-Ex(9-39)は、配列番号4のアミノ酸配列の第4位のリジン残基の側鎖のアミノ基に、リンカーであるPEG3を介して[125I]3-iodobenzoyl基([125I]IB)が結合し、かつ、C末端のカルボキシル基がアミド化されている。
Fmoc-DLSK(Boc-PEG3)QMEEEAVRLFIEWLK(Fmoc)NGGPSSGAPPPS-Rink Amide MBHA (7)(配列番号7)
上記式(7)で表される保護ペプチド樹脂Aの合成は、アドバンスケムテック社製のペプチド合成機(ACT90)を用いて固相合成法により行った。なお、式(7)において、Lys(Boc-PEG3)及びLys(Fmoc)以外は側鎖の保護基の表記を省略した。
Fmoc-QMEEEAVRLFIEWLK(Mmt)NGGPSSGAPPPS- Rink Amide MBHA (8)(配列番号8)
Fmoc-DLSK(Boc-PEG3)QMEEEAVRLFIEWLK(Mmt)NGGPSSGAPPPS-Rink Amide MBHA (9)(配列番号9)
得られた保護ペプチド樹脂Aを、トリフルオロ酢酸を用いる定法の脱保護条件(TFA-TIS-H2O-DT(95/2.5/2.5/2.5,v/v))で、室温で2時間処理して脱保護と樹脂からのペプチドの切り離しとを同時に行った。反応液から担体樹脂をろ別した後、TFAを留去し、残渣にエーテルを加えて得られる粗生成物の沈殿をろ取した。
得られた粗生成ペプチドを、HPLC分取装置(商品名:LC-8A-2、島津製作所製、カラム:ODS30x250mm)を用いて0.1%トリフルオロ酢酸を含む水―アセトニトリルの系で分取精製し、目的のペプチドの分画を得た。ついで、アセトニトリルを留去した後、凍結乾燥粉末とし、下記式(10)で表されるペプチド誘導体(配列番号10)をトリフルオロ酢酸塩として得た。下記式(10)で表されるペプチド誘導体は、(IB-PEG3)12-Ex(9-39)の標識前駆体である。
式(10)で表されるペプチド誘導体(410μg)を、アセト二トリル、Borate Buffer(pH7.8)に溶解させ、それに[125I]N-succinimidyl3-iodobenzoate([125I]SIB)を加え反応溶液をpH8.5~9.0に調整して30分間反応させることにより標識化を行った。その後、DMF及びピペリジンを加えることで脱保護反応を行い、目的物である(IB-PEG3)12-Ex(9-39)(式(6)で表されるペプチド誘導体)を得た(放射化学的収率:48.6%、放射化学的純度:>99%)。また、標識化に要した時間は2.5時間であった。なお、標識化に要した時間とは、標識前駆体を標識化して目的物である標識体を得るまでの時間であって、標識化合物との反応時間、標識化合物との反応後の脱保護反応時間、LC精製時間及び濃縮時間を含む(以下同様)。
下記式(11)で表されるペプチド誘導体(配列番号11)を調製した。なお、式(11)で表されるペプチド誘導体は、配列番号4のアミノ酸配列の第4位のリジン残基の側鎖のアミノ基に[125I]IBが直接結合し、かつ、C末端のカルボキシル基がアミド化されている。
Fmoc-DLSKQMEEEAVRLFIEWLK(Fmoc)NGGPSSGAPPPS-CONH2 (12) (配列番号12)
式(13)で表されるペプチド誘導体:(IB-PEG 3 )40-Ex(9-39)の合成
以下に示すように、下記式(13)で表されるペプチド誘導体(配列番号13)(以下、「(IB-PEG3)40-Ex(9-39)」ともいう)を調製した。なお、(IB-PEG3)40-Ex(9-39)は、配列番号5のアミノ酸配列の第40位のリジン残基の側鎖のアミノ基に、PEG3リンカーを介して[125I]IBが結合し、かつ、C末端のカルボキシル基がアミド化されている。
Fmoc-DLSK(Fmoc)QMEEEAVRLFIEWLK(Fmoc)NGGPSSGAPPPSK(Boc-PEG3)-Rink Amide MBHA (14)(配列番号14)
下記式(16)で表されるペプチド誘導体(配列番号16)を調製した。なお、式(16)で表されるペプチド誘導体は、配列番号5のアミノ酸配列の第32位のリジン残基の側鎖のアミノ基に[125I]IBが直接結合し、かつ、C末端のカルボキシル基がアミド化されている。
Fmoc-DLSK(Fmoc)QMEEEAVRLFIEWLK(Fmoc)NGGPSSGAPPPSK-CONH2 (17) (配列番号17)
式(6)で表されるペプチド誘導体((IB-PEG3)12-Ex(9-39))を用いて、体内分布実験、及び二次元イメージング解析を行った。
(IB-PEG3)12-Ex(9-39)(0.93μCi)を無麻酔の6週齢ddYマウス(雄性、体重30g)に静脈注射(尾静脈)により投与した。投与5分後、15分後、30分後、60分後、120分後に各臓器を摘出した(n=5)。各臓器の重量と放射能とを測定し、単位重量あたりの放射能から集積量(%dose/g)を算出した。その結果の一例を下記表1及び図1に示す。図1は、各臓器への(IB-PEG3)12-Ex(9-39)の集積の経時変化の一例を示すグラフである。
参考例1として、参考製造例1で調製した式(11)で表されるペプチド誘導体を用い、実施例1と同様にマウスの体内分布の測定を行った。その結果の一例を下記表2及び図2に示す。
(IB-PEG3)12-Ex(9-39)(5μCi/100μl)を無麻酔のMIP-GFPマウス(雄性、体重20g)に静脈注射により投与し、投与30分後及び60分後に膵臓を摘出した(n=1)。摘出した膵臓から切片を切り出し、切片をスライドガラス上に置き、その上にカバーガラスを載せた。切片の蛍光及び放射能(オートラジオグラフィー)は、画像解析装置(商品名:Typhoon 9410、GEヘルスケア社製)を用いて測定した(露光時間:21時間)。その結果の一例を図3レーン3~8に示す。
以下に示すように、下記式(18)で表されるペプチド誘導体(配列番号18)を用いて、SPECTによる三次元イメージングを行った。なお、式(18)で表されるペプチド誘導体は、配列番号4のアミノ酸配列の第4位のリジン残基の側鎖のアミノ基に、PEG3リンカーを介して[123I]3-iodobenzoyl基([123I]IB)が結合し、かつ、C末端のカルボキシル基がアミド化されている。
式(18)で表されるペプチド誘導体は、[125I]SIBに替えて[123I]SIBを用いた以外は、製造例1と同様の手順で調製した。
式(18)で表されるペプチド誘導体を用いてマウスのSPECT撮像を行った。式(18)で表されるペプチド誘導体(491μCi(18.2MBq)/190μl)を6週齢ddYマウス(雄性、体重約30g)に静脈注射により投与し、ペプチド誘導体の投与後20分からインフルラン吸入麻酔を開始した。ついで、ペプチド誘導体投与後30分からSPECT撮像を行った。SPECT撮像は、ガンマカメラ(製品名:SPECT2000H-40、日立メディコ製)を用いて下記の撮像条件で行った。得られた画像を下記の再構成条件で再構成処理を行った。
撮像条件
コリメータ :LEPH コリメータ
収集範囲 :360°
ステップ角度 :11.25°
収集時間 :1方向あたりの収集時間60秒
60秒ごと1フレーム×32フレーム(計32分間)
再構成条件
前処理フィルタ:Butterworthフィルタ(order:10、cutoff周波数:0.10)
式(13)で表されるペプチド誘導体((IB-PEG3)40-Ex(9-39))を用いて、体内分布実験、及び二次元イメージング解析を行った。
(IB-PEG3)40-Ex(9-39)(0.69μCi)を無麻酔の6週齢ddYマウス(雄性、体重30g)に静脈注射(尾静脈)により投与した。投与5分後、15分後、30分後、60分後、120分後に各臓器を摘出した(n=5)。各臓器の重量と放射能とを測定し、単位重量あたりの放射能から集積量(%dose/g)を算出した。その結果の一例を下記表6及び図5に示す。図5は、各臓器への(IB-PEG3)40-Ex(9-39)の集積の経時変化の一例を示すグラフである。
参考例2として、参考製造例2で製造した式(16)で表されるペプチド誘導体を用い、実施例2と同様にマウスの体内分布の測定を行った。その結果の一例を下記表7及び図6に示す。
(IB-PEG3)40-Ex(9-39)(5μCi/100μl)を無麻酔のMIP-GFPマウス(雄性、体重20g)に静脈注射により投与し、投与30分後及び60分後に膵臓を摘出した(n=1)。摘出した膵臓から切片を切り出し、切片をスライドガラス上に置き、その上にカバーガラスを載せた。切片の蛍光及び放射能(オートラジオグラフィー)は、画像解析装置(商品名:Typhoon 9410、GEヘルスケア社製)を用いて測定した(露光時間:19時間)。その結果の一例を図7のレーン3、4、7及び8に示す。
以下に示すように、下記式(19)で表されるペプチド誘導体(配列番号19)を用いて、SPECTによる三次元イメージングを行った。なお、式(19)で表されるペプチド誘導体は、配列番号5のアミノ酸配列の第32位のリジン残基の側鎖のアミノ基に、PEG3リンカーを介して[123I]3-iodobenzoyl基([123I]IB)が結合し、かつ、C末端のカルボキシル基がアミド化されている。
式(19)で表されるペプチド誘導体は、[125I]SIBに替えて[123I]SIBを用いた以外は、製造例2と同様の手順で調製した。
式(19)で表されるペプチド誘導体を用いてマウスのSPECT撮像を行った。式(18)で表されるペプチド誘導体(500μCi(18.5MBq))を6週齢ddYマウス(雄性、体重約30g)に静脈注射により投与し、ペプチド誘導体の投与後20分からインフルラン吸入麻酔を開始した。ついで、ペプチド誘導体投与後30分からSPECT撮像を行った。SPECT撮像は、ガンマカメラ(製品名:SPECT2000H-40、日立メディコ製)を用いて下記の撮像条件で行った。得られた画像を下記の再構成条件で再構成処理を行った。
撮像条件
コリメータ :LEPH コリメータ
収集範囲 :360°
ステップ角度 :11.25°
収集時間 :1方向あたりの収集時間60秒
60秒ごと1フレーム×32フレーム(計32分間)
再構成条件
前処理フィルタ:Butterworthフィルタ(order:10、cutoff周波数:0.14)
式(21)で表されるペプチド誘導体:(FB-PEG 3 )12-Ex4の合成
下記式(21)で表されるペプチド誘導体(配列番号21)(以下、「(FB-PEG3)12-Ex4」ともいう)を調製した。
式(22)で表されるペプチド誘導体に替えて下記式(23)で表される標識前駆体(220μg)を使用し、[18F]SFBとの反応時間を73分間にした以外は、製造例3と同様に標識化を行い、目的の式(24)で表されるペプチド誘導体(配列番号24)を得た(放射化学的収率:1.3%、放射化学的純度:>99%)。また、標識化に要した時間は2.9時間であった。
Fmoc-HGEGTFTSDLSKQMEEEAVRLFIEWLK(Fmoc)NGGPSSGAPPPS-CONH2 (23) (配列番号23)
式(25)で表されるペプチド誘導体:(IB-PEG 3 )12-Ex4の合成
式(10)で表されるペプチド誘導体に替えて式(22)で表されるペプチド誘導体(240μg)を標識前駆体として使用した以外は、製造例1の(4)と同様に標識化を行い、目的物である(IB-PEG3)12-Ex4(式(25)で表されるペプチド誘導体、配列番号25)を得た(放射化学的収率:18.7%、放射化学的純度:95.1%)。また、標識化に要した時間は3.5時間であった。なお、標識化に要した時間には、標識化合物との反応時間、HPLC精製時間、標識化合物との反応後の脱保護反応時間、LC精製時間及び濃縮時間を含む。
式(22)で表されるペプチド誘導体に替えて式(23)で表される標識前駆体(570μg)を使用し、[125I]SIBとの反応時間を174分間にした以外は、製造例4と同様に標識化を行い、目的の式(26)で表されるペプチド誘導体(配列番号26)を得た(放射化学的収率:18.4%、放射化学的純度:97.2%)。また、標識化に要した時間は4.6時間であった。
式(27)で表されるペプチド誘導体:(IB-PEG 3 )40-Ex4の合成
式(10)で表されるペプチド誘導体に替えて下記式(28)で表されるペプチド誘導体(配列番号28)(320μg)を標識前駆体として使用し、[125I]SIBとの反応時間を40分間にした以外は、製造例1の(4)と同様に標識化を行い、目的物である(IB-PEG3)40-Ex4(式(27)で表されるペプチド誘導体、配列番号27)を得た(放射化学的収率:32.4%、放射化学的純度:>99%)。また、標識化に要した時間は4.3時間であった。
式(28)で表されるペプチド誘導体に替えて式(29)で表される標識前駆体(510μg)を使用し、[125I]SIBとの反応時間を61分間にした以外は、製造例5と同様に標識化を行い、目的の式(30)で表されるペプチド誘導体(配列番号30)を得た(放射化学的収率:28.3%、放射化学的純度:>99%)。また、標識化に要した時間は4.5時間であった。
Fmoc-HGEGTFTSDLSK(Fmoc)QMEEEAVRLFIEWLK(Fmoc)NGGPSSGAPPPSK-CONH2 (29) (配列番号29)
下記表11に示す4種類のポリペプチド(式(31)~(34)、いずれもコールド体)を用いてBinding Assayを行った。
Binding Assayは以下の手順で行った.まず、マウスから単離した膵島を50mlチューブに回収し、遠心(2000rpm、2分)した後、冷PBS20mLで1回洗浄した。トリプシン-EDTA(トリプシン-EDTA(0.05%/0.53mM)3mLに、PBSを含む0.53mM EDTA(pH7.4(NaOH))12mLを加えたもの)を15mL加え、37℃で振とうしながら1分間インキュベートした後、直ちに氷上に置いた。ついで、スポイト付10mLピペットで泡立てることなく勢いよく20回ピペッティングした後、冷PBSを最終量が30mLになるように加えた。遠心(3000rpm、2分)した後、冷PBS 30mLで2回洗浄した。上清を除去して膵島細胞サンプルを得た。得られた膵島細胞サンプルは-80℃で保存した。
式(25)で表されるペプチド誘導体((IB-PEG3)12-Ex4)を用いて、体内分布実験、及び二次元イメージング解析を行った。
(IB-PEG3)12-Ex4(0.77μCi)を無麻酔の6週齢ddYマウス(雄性、体重30g)に静脈注射(尾静脈)により投与した。投与5分後、15分後、30分後、60分後、120分後に各臓器を摘出した(n=5)。各臓器の重量と放射能とを測定し、単位重量あたりの放射能から集積量(%dose/g)を算出した。その結果の一例を下記表12及び13、並びに図9に示す。図9は、各臓器への(IB-PEG3)12-Ex4の集積の経時変化の一例を示すグラフである。
(IB-PEG3)12-Ex4(5.6μCi/100μl)を無麻酔のMIP-GFPマウス(雄性、体重20g)に静脈注射により投与し、投与30分後に膵臓を摘出した(n=1)。摘出した膵臓から切片を切り出し、切片をスライドガラス上に置き、その上にカバーガラスを載せた。切片の蛍光及び放射能(オートラジオグラフィー)は、画像解析装置(商品名:Typhoon 9410、GEヘルスケア社製)を用いて測定した(露光時間:24時間)。その結果の一例を図10のBlocking(-)に示す。
下記式(35)で表されるペプチド誘導体(配列番号35)を用いて、SPECTによる三次元イメージングを行った。
式(35)で表されるペプチド誘導体は、[125I]SIBに替えて[123I]SIBを用いた以外は、製造例4と同様の手順で調製した。
式(35)で表されるペプチド誘導体(153μCi(5.66MBq)/250μl)を6週齢ddYマウス(雄性、体重約30g)に静脈注射により投与し、ペプチド誘導体の投与後20分からインフルラン吸入麻酔を開始した。ついで、ペプチド誘導体投与後30分からSPECT撮像を行った。SPECT撮像は、ガンマカメラ(製品名:SPECT2000H-40、日立メディコ製)を用いて下記の撮像条件で行った。得られた画像を下記の再構成条件で再構成処理を行った。
撮像条件
コリメータ :LEPH コリメータ
収集範囲 :360°
ステップ角度 :11.25°
収集時間 :1方向あたりの収集時間60秒
60秒ごと1フレーム×32フレーム(計32分間)
再構成条件
前処理フィルタ:Butterworthフィルタ(order:10、cutoff周波数:0.10)
式(27)で表されるペプチド誘導体((IB-PEG3)40-Ex4)を用いて、体内分布実験、及び二次元イメージング解析を行った。
(IB-PEG3)40-Ex4(0.74μCi)を無麻酔の6週齢ddYマウス(雄性、体重30g)に静脈注射(尾静脈)により投与した。投与5分後、15分後、30分後、60分後、120分後に各臓器を摘出した(n=5)。各臓器の重量と放射能とを測定し、単位重量あたりの放射能から集積量(%dose/g)を算出した。その結果の一例を下記表14及び15、並びに図12に示す。図12は、各臓器への(IB-PEG3)40-Ex4の集積の経時変化の一例を示すグラフである。
(IB-PEG3)40-Ex4(5.6μCi/100μl)を無麻酔のMIP-GFPマウス(雄性、体重20g)に静脈注射により投与し、投与30分後に膵臓を摘出した(n=1)。摘出した膵臓から切片を切り出し、切片をスライドガラス上に置き、その上にカバーガラスを載せた。切片の蛍光及び放射能(オートラジオグラフィー)は、画像解析装置(商品名:Typhoon 9410、GEヘルスケア社製)を用いて測定した(露光時間:48時間)。その結果の一例を図13のBlocking(-)に示す。
下記式(36)で表されるペプチド誘導体(配列番号36)を用いて、SPECTによる三次元イメージングを行った。
式(36)で表されるペプチド誘導体は、[125I]SIBに替えて[123I]SIBを用いた以外は、製造例5と同様の手順で調製した。
式(36)で表されるペプチド誘導体(154μCi(5.7MBq)/100μl)を6週齢ddYマウス(雄性、体重約30g)に静脈注射により投与し、ペプチド誘導体の投与後20分からインフルラン吸入麻酔を開始した。ついで、ペプチド誘導体投与後30分からSPECT撮像を行った。SPECT撮像は、ガンマカメラ(製品名:SPECT2000H-40、日立メディコ製)を用いて下記の撮像条件で行った。得られた画像を下記の再構成条件で再構成処理を行った。
撮像条件
コリメータ :LEPH コリメータ
収集範囲 :360°
ステップ角度 :11.25°
収集時間 :1方向あたりの収集時間60秒
60秒ごと1フレーム×32フレーム(計32分間)
再構成条件
前処理フィルタ:Butterworthフィルタ(order:10、cutoff周波数:0.10)
式(24)で表されるペプチド誘導体((FB-PEG3)12-Ex4)を用いて、体内分布実験、及び二次元イメージング解析を行った。
(FB-PEG3)12-Ex4(5μCi)を無麻酔の6週齢ddYマウス(雄性、体重30g)に静脈注射(尾静脈)により投与した。投与5分後、15分後、30分後、60分後、120分後に各臓器を摘出した(n=5)。各臓器の重量と放射能とを測定し、単位重量あたりの放射能から集積量(%dose/g)を算出した。その結果の一例を下記表16及び17、並びに図15に示す。図15は、各臓器への(FB-PEG3)12-Ex4の集積の経時変化の一例を示すグラフである。
(FB-PEG3)12-Ex4(292μCi/220μl)を無麻酔のMIP-GFPマウス(雄性、体重20g)に静脈注射により投与し、投与15分後に膵臓を摘出した(n=1)。摘出した膵臓から切片を切り出し、切片をスライドガラス上に置き、その上にカバーガラスを載せた。切片の蛍光及び放射能(オートラジオグラフィー)は、画像解析装置(商品名:Typhoon 9410、GEヘルスケア社製)を用いて測定した(露光時間:24時間)。その結果の一例を図16に示す。
式(37)で表されるペプチド誘導体:(IB-ePEG12)12-Ex4の合成
Fmoc-Lys(Boc-ePEG12)をFmoc-Lys(Boc-PEG3)に替えて使用した以外は、製造例3と同様に式(38)で表されるペプチド誘導体(配列番号38)を製造した。ついで、得られた式(38)で表されるペプチド誘導体(540μg)を式(10)で表されるペプチド誘導体に替えて使用した以外は、製造例1の(4)と同様に標識化を行い、目的物である(IB-ePEG12)12-Ex4(式(37)で表されるペプチド誘導体、配列番号37)を得た(放射化学的収率:41.8%、放射化学的純度:95.7%)。また、標識化に要した時間は2.75時間であった。なお、標識化に要した時間には、標識化合物との反応時間、HPLC精製時間、標識化合物との反応後の脱保護反応時間、LC精製時間及び濃縮時間を含む。
式(37)で表されるペプチド誘導体((IB-ePEG12)12-Ex4)を用いて体内分布実験を行った。
(IB-ePEG12)12-Ex4(0.21μCi)を無麻酔の6週齢ddYマウス(雄性、体重30g)に静脈注射(尾静脈)により投与した。投与5分後、15分後、30分後、60分後、120分後に各臓器を摘出した(n=5)。各臓器の重量と放射能とを測定し、単位重量あたりの放射能から集積量(%dose/g)を算出した。その結果の一例を下記表18及び19、並びに図17に示す。図17は、各臓器への(IB-ePEG12)12-Ex4の集積の経時変化の一例を示すグラフである。
下記式(39)で表されるペプチド誘導体(配列番号39)を用いて、SPECTによる三次元イメージングを行った。
式(39)で表されるペプチド誘導体は、[125I]SIBに替えて[123I]SIBを用いた以外は、製造例6と同様の手順で調製した。
式(36)のペプチド誘導体に替えて式(39)で表されるペプチド誘導体を使用し、投与量を233μCi(8.6MBq)/120μl)とした以外は、実施例8と同様の条件でSPECT撮像を行った。その結果の一例を図18に示す。図18は、撮像したマウスにおける投与した放射能に対する臓器1g当たりの割合(臓器1g当たりの放射能集積率(%dose/g))の一例を示すグラフである。図18に示すように、肝臓及び大腸などでの集積がほとんど見られず良好な結果が得られた。また、撮像した画像において、非侵襲的に膵臓の位置を確認することができた(データ示さず)。
配列番号2:本発明のペプチド誘導体のアミノ酸配列の一例
配列番号3:本発明のペプチド誘導体のアミノ酸配列の一例
配列番号4:本発明のペプチド誘導体のアミノ酸配列の一例
配列番号5:本発明のペプチド誘導体のアミノ酸配列の一例
配列番号6:製造例1で製造したペプチド誘導体のアミノ酸配列
配列番号7:製造例1で製造した保護ペプチド樹脂Aのアミノ酸配列
配列番号8:製造例1で製造した保護ペプチド樹脂A1のアミノ酸配列
配列番号9:製造例1で製造した保護ペプチド樹脂A2のアミノ酸配列
配列番号10:製造例1で製造した標識前駆体のアミノ酸配列
配列番号11:参考製造例1で製造したペプチド誘導体のアミノ酸配列
配列番号12:参考製造例1で使用した標識前駆体のアミノ酸配列
配列番号13:製造例2で製造したペプチド誘導体のアミノ酸配列
配列番号14:製造例2で製造した保護ペプチド樹脂Bのアミノ酸配列
配列番号15:製造例2で製造した標識前駆体のアミノ酸配列
配列番号16:参考製造例2で製造したペプチド誘導体のアミノ酸配列
配列番号17:参考製造例2で使用した標識前駆体のアミノ酸配列
配列番号18:実施例2で使用したペプチド誘導体のアミノ酸配列
配列番号19:実施例4で使用したペプチド誘導体のアミノ酸配列
配列番号20:exendin(9-39)のアミノ酸配列
配列番号21:製造例3で製造したペプチド誘導体のアミノ酸配列
配列番号22:製造例3で製造した標識前駆体のアミノ酸配列
配列番号23:参考製造例3で製造した標識前駆体のアミノ酸配列
配列番号24:参考製造例3で製造したペプチド誘導体のアミノ酸配列
配列番号25:製造例4で製造したペプチド誘導体のアミノ酸配列
配列番号26:参考製造例4で製造したペプチド誘導体のアミノ酸配列
配列番号27:製造例5で製造したペプチド誘導体のアミノ酸配列
配列番号28:製造例5で製造した標識前駆体のアミノ酸配列
配列番号29:参考製造例5で製造した標識前駆体のアミノ酸配列
配列番号30:参考製造例5で製造したペプチド誘導体のアミノ酸配列
配列番号31:Binding Assayで使用したポリペプチドのアミノ酸配列
配列番号32:Binding Assayで使用したポリペプチドのアミノ酸配列
配列番号33:Binding Assayで使用したポリペプチドのアミノ酸配列
配列番号34:Binding Assayで使用したポリペプチドのアミノ酸配列
配列番号35:実施例6で使用したペプチド誘導体のアミノ酸配列
配列番号36:実施例8で使用したペプチド誘導体のアミノ酸配列
配列番号37:製造例6で製造したペプチド誘導体のアミノ酸配列
配列番号38:製造例6で製造した標識前駆体のアミノ酸配列
配列番号39:実施例10で使用したペプチド誘導体のアミノ酸配列
Claims (14)
- 下記一般式(I)で表されるペプチド誘導体。
ExPは、exendin-4:
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (配列番号1)
のアミノ酸配列を完全に又は部分的に有する下記式(1)のアミノ酸配列で表されるポリペプチドを示し、
Ex4(x-y)-Kn (1)
式(1)において、Ex4(x-y)は、配列番号1のアミノ酸配列のx位からy位のアミノ酸配列を示し、xは1~9の整数であり、yは30~39の整数であり、Kは、リジンを示し、nは、0又は1であり、
ポリペプチドExPのN末端のα-アミノ基は、非修飾であるか、電荷を有さない修飾基により修飾されているか、又は-L-Z基が結合しており、
ポリペプチドExPのC末端のカルボキシル基は、アミド化されており、
-L-Z基は、上記式(1)のアミノ酸配列で表されるポリペプチドのアミノ酸の側鎖、又はN末端のα-アミノ基に結合する下記式(II)で表される基を示し、
式(1)におけるnが1である場合、lは0、1又は2であり、mは1~30の整数であり、式(1)におけるnが0である場合、lは0~8の整数であり、mは0~30の整数であり、
Zは、放射性核種又はその同位体を含む標識基を示す。 - Ex4(x-y)-Knは、下記式(2)~(5)のいずれかのアミノ酸配列である、請求項1記載のペプチド誘導体。
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (2) (配列番号2)
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK (3) (配列番号3)
DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (4) (配列番号4)
DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK (5) (配列番号5) - -L-Z基は、配列番号1のアミノ酸配列の12位に相当するリジンの側鎖のアミノ基、又は式(1)のKの側鎖のアミノ基に結合している、請求項1又は2に記載のペプチド誘導体。
- Zは、放射性核種を含む標識基である、請求項1から4のいずれかに記載のペプチド誘導体。
- 請求項1から5のいずれかに記載のペプチド誘導体を含む組成物。
- 請求項5に記載のペプチド誘導体を含むイメージング用試薬。
- 下記一般式(IV)で表されるペプチド誘導体。
ExP-Pは、exendin-4:
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (配列番号1)
のアミノ酸配列を完全に又は部分的に有する下記式(1)のアミノ酸配列で表されるポリペプチドを示し、
Ex4(x-y)-Kn (1)
式(1)において、Ex4(x-y)は、配列番号1のアミノ酸配列のx位からy位のアミノ酸配列を示し、xは1~9の整数であり、yは30~39の整数であり、Kは、リジンを示し、nは、0又は1であり、
ポリペプチドExP-PのN末端のα-アミノ基は、保護基又は-L-Y基が結合しているか、電荷を有さない修飾基により修飾されているか、若しくは非修飾であり、
ポリペプチドExP-PのC末端のカルボキシル基は、アミド化されており、
-L-Y基は、上記式(1)のアミノ酸配列で表されるポリペプチドのアミノ酸の側鎖、又はN末端のα-アミノ基に結合する下記式(V)で表される基を示し、
式(1)におけるnが1である場合、lは0、1又は2であり、mは1~30の整数であり、式(1)におけるnが0である場合、lは0~8の整数であり、mは0~30の整数であり、
Yは、水素原子、又は放射性標識導入基を示す。 - Ex4(x-y)-Knは、下記式(2)~(5)のいずれかのアミノ酸配列である、請求項8記載のペプチド誘導体。
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (2) (配列番号2)
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK (3) (配列番号3)
DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (4) (配列番号4)
DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK (5) (配列番号5) - 請求項5に記載のペプチド誘導体を製造するためのキットであって、
Zが放射性核種の非放射性同位体を含む標識基である請求項1から4のいずれかに記載のペプチド誘導体、及び/若しくは請求項8又は9に記載のペプチド誘導体を含む、キット。 - 膵β細胞をイメージングするための方法であって、
請求項5記載のペプチド誘導体を予め投与された被検体から前記ペプチド誘導体の放射性核種のシグナルを検出することを含む、イメージング方法。 - 前記検出されたシグナルを再構成処理して画像に変換し表示することを含む、請求項11記載のイメージング方法。
- 請求項5記載のペプチド誘導体を投与された被検体から前記ペプチド誘導体のシグナルを検出すること、及び、
検出したペプチド誘導体のシグナルから膵島量を算出することを含む、膵島量の測定方法。 - 算出した膵島量を提示することを含む、請求項13記載の膵島量の測定方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011554317A JP5669765B2 (ja) | 2010-10-08 | 2011-10-07 | ペプチド誘導体及びその使用 |
EP11830776.8A EP2660249B1 (en) | 2010-10-08 | 2011-10-07 | Peptide derivative and use thereof |
CN201180048275.7A CN103189388B (zh) | 2010-10-08 | 2011-10-07 | 肽衍生物及其用途 |
KR20137010966A KR101511660B1 (ko) | 2010-10-08 | 2011-10-07 | 펩티드 유도체 및 그 사용 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39137410P | 2010-10-08 | 2010-10-08 | |
JP2010229009 | 2010-10-08 | ||
JP2010-229009 | 2010-10-08 | ||
US61/391374 | 2010-10-08 | ||
US201161496831P | 2011-06-14 | 2011-06-14 | |
US61/496831 | 2011-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012046845A1 true WO2012046845A1 (ja) | 2012-04-12 |
Family
ID=45927837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/073234 WO2012046845A1 (ja) | 2010-10-08 | 2011-10-07 | ペプチド誘導体及びその使用 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2660249B1 (ja) |
JP (1) | JP5669765B2 (ja) |
KR (1) | KR101511660B1 (ja) |
CN (1) | CN103189388B (ja) |
WO (1) | WO2012046845A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014178229A1 (ja) * | 2013-04-30 | 2014-11-06 | 国立大学法人京都大学 | 放射性ガリウム結合部位を有するポリペプチド、及び、その放射性ガリウム錯体 |
EP2927239A4 (en) * | 2012-11-30 | 2016-07-13 | Univ Kyoto | POLYPEPTIDE AND METHOD OF IMAGING |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104945499B (zh) * | 2014-03-31 | 2019-12-10 | 博瑞生物医药(苏州)股份有限公司 | 结构修饰的glp-1类似物及其制备方法 |
CN108285464B (zh) * | 2018-03-09 | 2020-05-12 | 北京大学 | 放射性分子探针及其在活体胰岛检测中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1964848A1 (en) * | 2007-03-01 | 2008-09-03 | Bayer Schering Pharma Aktiengesellschaft | Radiofluorination methods |
KR20110074614A (ko) * | 2009-03-19 | 2011-06-30 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 췌도 이미징용 분자 프로브 전구체 및 그 사용 |
BRPI1013626B8 (pt) * | 2009-03-20 | 2021-05-25 | Hanmi Holdings Co Ltd | método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico |
CN102282164B (zh) * | 2009-08-10 | 2015-09-16 | 国立大学法人京都大学 | 胰岛成像用分子探针及其前体,以及它们的使用 |
WO2011040460A1 (ja) * | 2009-09-30 | 2011-04-07 | 国立大学法人京都大学 | 膵島イメージング用分子プローブ及びその使用 |
-
2011
- 2011-10-07 JP JP2011554317A patent/JP5669765B2/ja active Active
- 2011-10-07 KR KR20137010966A patent/KR101511660B1/ko active IP Right Grant
- 2011-10-07 WO PCT/JP2011/073234 patent/WO2012046845A1/ja active Application Filing
- 2011-10-07 EP EP11830776.8A patent/EP2660249B1/en active Active
- 2011-10-07 CN CN201180048275.7A patent/CN103189388B/zh active Active
Non-Patent Citations (8)
Title |
---|
BLAKELY B. ET AL.: "Formulation and characterization of radio-opaque conjugated in situ gelling materials.", J. BIOMED. MATER. RES. B APPL. BIOMATER., vol. 93B, no. 1, April 2010 (2010-04-01), pages 9 - 17, XP055086420 * |
DATABASE MICAD [online] 20 February 2008 (2008-02-20), CHENG K.T.: "[18F]FB-NH-mini-PEG-E{E[c(RGDyK)]2}2. (http://www.ncbi.nlm.nih.gov/books/NBK23235)", XP003032712, retrieved from NCBI (bookshelf) Database accession no. NBK23235 * |
DATABASE MICAD [online] 6 April 2010 (2010-04-06), LEUNG K.: "3-(4-Hydroxy-3-[125I]iodophenyl) propionate-exendin(9-39). (http://ncbi.nlm.nih.gov/books/NBK44818)", XP003032711, retrieved from NCBI (bookshelf) Database accession no. NBK44818 * |
LIU Z. ET AL.: "(68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin ALPHAvBETA3 PET imaging", EUR. J. NUCL. MED. MOL. IMAGING, vol. 36, no. 6, June 2009 (2009-06-01), pages 947 - 957, XP019706091 * |
MELENDEZ-ALAFORT L. ET AL.: "Detection of sites of infection in mice using 99mTc-labeled PN(2)S-PEG conjugated to UBI and 99mTc-UBI: a comparative biodistribution study.", NUCL. MED. BIOL., vol. 36, no. 1, January 2009 (2009-01-01), pages 57 - 64, XP025923965 * |
MUKAI E. ET AL.: "GLP-1 receptor antagonist as a potential probe for pancreatic beta-cell imaging.", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 389, no. 3, 20 November 2009 (2009-11-20), pages 523 - 526, XP055086413 * |
See also references of EP2660249A4 * |
WILD D. ET AL.: "Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.", J. NUCL. MED., vol. 51, no. 7, July 2010 (2010-07-01), pages 1059 - 1067, XP055037208 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2927239A4 (en) * | 2012-11-30 | 2016-07-13 | Univ Kyoto | POLYPEPTIDE AND METHOD OF IMAGING |
WO2014178229A1 (ja) * | 2013-04-30 | 2014-11-06 | 国立大学法人京都大学 | 放射性ガリウム結合部位を有するポリペプチド、及び、その放射性ガリウム錯体 |
JPWO2014178229A1 (ja) * | 2013-04-30 | 2017-02-23 | 国立大学法人京都大学 | 放射性ガリウム結合部位を有するポリペプチド、及び、その放射性ガリウム錯体 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2012046845A1 (ja) | 2014-02-24 |
EP2660249A4 (en) | 2014-04-16 |
JP5669765B2 (ja) | 2015-02-18 |
KR101511660B1 (ko) | 2015-04-13 |
EP2660249B1 (en) | 2019-07-10 |
CN103189388B (zh) | 2015-05-06 |
CN103189388A (zh) | 2013-07-03 |
KR20130103539A (ko) | 2013-09-23 |
EP2660249A1 (en) | 2013-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5700835B2 (ja) | 膵島イメージング用分子プローブ及びその使用 | |
US20140127128A1 (en) | Molecular Probe for Imaging of Pancreatic Islets and Use of the Same | |
US20150231284A1 (en) | Molecular probe for imaging of pancreatic islet and the precursor, and use of the same | |
JP5608867B2 (ja) | 膵島イメージング用分子プローブ及びその使用 | |
JP5669765B2 (ja) | ペプチド誘導体及びその使用 | |
US9278146B2 (en) | Peptide derivative and use of the same | |
WO2012108476A1 (ja) | 放射性標識されたポリペプチドの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2011554317 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11830776 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20137010966 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011830776 Country of ref document: EP |